

(19) Europäisches Patentamt  
 European Patent Office  
 Office européen des brevets



(11) Publication number: 0 463 756 B1

(12)

## EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: 19.04.95 (51) Int. Cl.<sup>6</sup>: C07D 487/04, A61K 31/505, A61K 31/635  
 (21) Application number: 91305137.1  
 (22) Date of filing: 07.06.91

The file contains technical information submitted after the application was filed and not included in this specification

- (54) Pyrazolopyrimidinone antianginal agents.

<p>(30) Priority: 20.06.90 GB 9013750    (43) Date of publication of application:  <b>02.01.92 Bulletin 92/01</b>    (45) Publication of the grant of the patent:  <b>19.04.95 Bulletin 95/16</b>    (84) Designated Contracting States:  <b>AT BE CH DE DK ES FR GB GR IT LI LU NL SE</b>    (56) References cited:  <b>EP-A- 0 201 188</b></p> <p><b>PATENT ABSTRACTS OF JAPAN unexamined applications, C field, vol. 13, no. 56, February 8, 1989 THE PATENT OFFICE JAPANESE GOVERNMENT page 10 C 566</b></p> <p>(73) Proprietor: <b>Pfizer Limited</b>  <b>Ramsgate Road</b>  <b>Sandwich</b>  <b>Kent CT13 9NJ (GB)</b>    (84) Designated Contracting States:  <b>GB</b></p> <p>(73) Proprietor: <b>PFIZER INC.</b></p>	<p>235 East 42nd Street    New York, N.Y. 10017 (US)    (84) Designated Contracting States:  <b>BE CH DE DK ES FR GR IT LI LU NL SE AT</b></p> <p>(72) Inventor: <b>Bell, Andrew Simon</b>  <b>Pfizer Central Research</b>  <b>Sandwich,</b>  <b>Kent CT13 9NJ (GB)</b>    Inventor: <b>Brown, David, Dr.</b>  <b>Pfizer Central Research</b>  <b>Sandwich,</b>  <b>Kent CT13 9NJ (GB)</b>    Inventor: <b>Terrett, Nicholas Kenneth, Dr.</b>  <b>Pfizer Central Research</b>  <b>Sandwich,</b>  <b>Kent CT13 9NJ (GB)</b></p> <p>(74) Representative: <b>Moore, James William, Dr.</b>  <b>Pfizer Limited</b>  <b>Ramsgate Road</b>  <b>Sandwich</b>  <b>Kent CT13 9NJ (GB)</b></p>
---	--

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).


**Description**

This invention relates to a series of pyrazolo[4,3-d]pyrimidin-7-ones, which are potent and selective inhibitors of cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE), having utility in a variety of therapeutic areas including the treatment of various cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.

The compounds of the invention exhibit selectivity for inhibition of cGMP PDEs rather than cyclic adenosine 3',5'-monophosphate phosphodiesterases (cAMP PDEs) and, as a consequence of this selective PDE inhibition, cGMP levels are elevated, which in turn can give rise to beneficial platelet anti-aggregatory, anti-vasospastic and vasodilatory activity, as well as potentiation of the effects of endothelium-derived relaxing factor (EDRF) and nitrovasodilators. Thus the compounds have utility in the treatment of a number of disorders, including stable, unstable and variant (Prinzmetal) angina, hypertension, congestive heart failure, atherosclerosis, conditions of reduced blood vessel patency e.g. post-percutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, and diseases characterised by disorders of gut motility, e.g. irritable bowel syndrome (IBS).

European patent application EP-A-0201188 discloses certain pyrazolo[4,3-d]pyrimidin-7-ones as adenosine receptor antagonists and PDE inhibitors, useful in the treatment of cardiovascular disorders such as heart failure or cardiac insufficiency. However these compounds are neither particularly potent PDE inhibitors, nor are they claimed to be selective inhibitors of cGMP PDE.

The compounds of the present invention are of the formula (I):



wherein

R¹ is H, C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>3</sub>-C<sub>5</sub> cycloalkyl or C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl;

R² is H, C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by OH, C<sub>1</sub>-C<sub>3</sub> alkoxy or C<sub>3</sub>-C<sub>6</sub> cycloalkyl, or C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl;

R³ is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl or (C<sub>3</sub>-C<sub>6</sub> cycloalkyl)C<sub>1</sub>-C<sub>6</sub> alkyl;

R⁴ taken together with the nitrogen atom to which it is attached completes a pyrrolidinyl, piperidino, morpholino, or 4-N-(R⁶)-piperazinyl group;

R⁵ is H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, NR⁷R⁸, or CONR⁷R⁸;

R⁶ is H, C<sub>1</sub>-C<sub>6</sub> alkyl, (C<sub>1</sub>-C<sub>3</sub> alkoxy)C<sub>2</sub>-C<sub>6</sub> alkyl, hydroxy C<sub>2</sub>-C<sub>6</sub> alkyl, (R⁷R⁸N)C<sub>2</sub>-C<sub>6</sub> alkyl, (R⁷R⁸NCO)-C<sub>1</sub>-C<sub>6</sub> alkyl, CONR⁷R⁸, CSNR⁷R⁸ or C(NH)NR⁷R⁸;

R⁷ and R⁸ are each independently H, C<sub>1</sub>-C<sub>4</sub> alkyl, (C<sub>1</sub>-C<sub>3</sub> alkoxy)C<sub>2</sub>-C<sub>4</sub> alkyl or hydroxy C<sub>2</sub>-C<sub>4</sub> alkyl; and pharmaceutically acceptable salts thereof.

In the above definition, unless otherwise indicated, alkyl or perfluoroalkyl groups having three or more carbon atoms may be straight or branched chain. In addition alkenyl or alkynyl groups having four or more carbon atoms, or alkoxy groups having three carbon atoms, may be straight or branched chain.

The compounds of formula (I) may contain one or more asymmetric centres and thus they can exist as enantiomers or diastereoisomers. The invention includes both mixtures and separate individual isomers.

The compounds of formula (I) may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers.

Also included in the invention are radiolabelled derivatives of compounds of formula (I) which are suitable for biological studies.

5 The pharmaceutically acceptable salts of the compounds of formula (I) which contain a basic centre are acid addition salts formed with pharmaceutically acceptable acids. Examples include the hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, citrate, fumarate, gluconate, lactate, maleate, succinate and tartrate salts. Compounds of the formula (I) can also provide pharmaceutically acceptable metal salts, in particular alkali metal salts, with bases. Examples include the 10 sodium and potassium salts.


A preferred group of compounds of the formula (I) is that wherein R<sup>1</sup> is H, methyl or ethyl; R<sup>2</sup> is C<sub>1</sub>-C<sub>3</sub> alkyl optionally substituted by OH or methoxy; R<sup>3</sup> is C<sub>2</sub>-C<sub>3</sub> alkyl or allyl; R<sup>4</sup> taken together with the nitrogen atom to which it is attached completes a piperidino or 4-N-(R<sup>6</sup>) piperazinyl group; R<sup>5</sup> is H, NR<sup>7</sup>R<sup>8</sup> or CONR<sup>7</sup>R<sup>8</sup>; R<sup>6</sup> is H, C<sub>1</sub>-C<sub>3</sub> alkyl, hydroxy C<sub>2</sub>-C<sub>3</sub> alkyl, CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> or C(NH)NR<sup>7</sup>R<sup>8</sup>; and R<sup>7</sup> and R<sup>8</sup> 15 are each independently H or methyl.

A particularly preferred group of compounds of the formula (I) is that wherein R<sup>1</sup> is methyl; R<sup>2</sup> is n-propyl; R<sup>3</sup> is ethyl, n-propyl or allyl; R<sup>4</sup> taken together with the nitrogen atom to which it is attached completes a 4-N-(R<sup>6</sup>) piperazinyl group; R<sup>5</sup> is H; and R<sup>6</sup> is H, C<sub>1</sub>-C<sub>3</sub> alkyl or 2-hydroxyethyl.

Especially preferred individual compounds of the invention include:

20 5-[2-allyloxy-5-(4-methylpiperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimdin-7-one;  
 5-[2-ethoxy-5-(piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimdin-7-one;  
 5-[2-ethoxy-5-(4-methylpiperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimdin-7-one;  
 5-[2-ethoxy-5-[4-(2-propyl)piperazinylsulphonyl]phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimdin-7-one;  
 5-[2-ethoxy-5-[4-(2-hydroxyethyl)piperazinylsulphonyl]phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimdin-7-one;  
 30 1-methyl-5-[5-(piperazinylsulphonyl)-2-n-propoxyphenyl]-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimdin-7-one;  
 and 5-[5-[4-(2-hydroxyethyl)piperazinylsulphonyl]-2-n-propoxyphenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimdin-7-one.

The compounds of the general formula (I) may be prepared by the reaction of a compound of the 35 general formula (II):



50 (wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as previously defined, and Y represents a halogen atom, preferably a chlorine atom) with a compound of the general formula (III):

5




wherein R<sup>4</sup> and R<sup>5</sup> are as previously defined.

- 10 The reaction is generally carried out at room temperature, preferably in the presence of a solvent, for example an alkanol containing one to three carbon atoms, using an excess of (III) to scavenge the acid by-product (HY).

Compounds of the general formula (II) may be prepared from compounds of the general formula (IV):

15

20



- 25 (wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as previously defined) by the application of known methods for the introduction of a SO<sub>2</sub>Y group (wherein Y is as previously defined) into an aromatic ring, for example, when Y represents a chlorine atom, by the action of chlorosulphonic acid at or near 0 °C.



When R<sup>3</sup> is a group susceptible to removal under the chlorosulphonylation conditions, e.g. allyl, said group can be introduced in the final stage of the synthesis. Thus the phenol of the general formula (IV), 30 wherein R<sup>3</sup> is H, and R<sup>1</sup> and R<sup>2</sup> are as previously defined, which is obtainable by Pd°-mediated deprotection of the O-allyl analogue as illustrated by Example 25, is chlorosulphonylated to provide a compound of the general formula (II), wherein Y is Cl, R<sup>3</sup> is H, and R<sup>1</sup> and R<sup>2</sup> are as previously defined. The latter is then reacted with the appropriate amine (III) to afford a compound of the general formula (I), wherein R<sup>3</sup> is H, and R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are as previously defined, which is finally O-alkylated to furnish a 35 compound of the general formula (I), wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as defined for formula (I). The alkylation may be effected under standard conditions using the appropriate alkyl halide, e.g. allyl bromide, in the presence of a base such as potassium carbonate, in a suitable solvent, e.g. 2-butanone, at the reflux temperature of the reaction mixture. Alternatively, the alkylation may be achieved under conventional Mitsunobu reaction conditions.

- 40 In the case of other compounds of formula (IV) which may be incompatible with the chlorosulphonylation reaction conditions, e.g. those wherein R<sup>2</sup> is hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, the hydroxy group can be protected with an acyl group such as acetyl or benzoyl. Said protecting group is subsequently removed at the final stage of the synthesis, under standard base hydrolysis conditions, to give compounds of the general formula (I) wherein R<sup>2</sup> is hydroxy C<sub>1</sub>-C<sub>6</sub> alkyl, and R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as defined for formula (I). 45 These latter compounds may also be obtained incidentally, as by-products, by chlorosulphonylation of the corresponding alkoxy analogues, i.e. compounds of the general formula (IV) wherein R<sup>2</sup> is (C<sub>1</sub>-C<sub>3</sub> alkoxy)C<sub>1</sub>-C<sub>6</sub> alkyl, followed by reaction of the crude product with the required amine (III), as illustrated by Example 48.

50

55

Compounds of the general formula (IV) may be prepared from compounds of the general formula (V):





15 (V)

(VI)

(wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as previously defined) by the application of known cyclisation methods for pyrimidinone ring formation. Thus, for example, the cyclisation may be effected by the treatment of (V) with 20 a base such as sodium hydroxide or potassium carbonate, optionally in the presence of hydrogen peroxide, in an ethanol-water medium at reflux temperature for 2-40 hours. Under these conditions the related nitrile of general formula (VI), wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as previously defined, may also be employed as the precursor to (IV).

In an alternative cyclisation procedure, compounds of the general formula (IV) may be obtained by 25 treatment of (V) with polyphosphoric acid at or near 140 °C for 6-18 hours.

Compounds of the general formulae (V) and (VI) may be prepared from compounds of the general formulae (VII) and (VIII) respectively:



40 (VII)

(VIII)

(wherein R<sup>1</sup> and R<sup>2</sup> are as previously defined) by reaction with a compound of general formula (IX):



(IX)

55 (wherein R<sup>3</sup> and Y are as previously defined).

The reaction is generally carried out using an excess of (IX) in the presence of an excess of an aliphatic tertiary amine such as triethylamine to act as scavenger for the acid by-product (HY), optionally in the presence of a catalyst such as 4-dimethylamino-pyridine, in an inert solvent such as dichloromethane at

0 °C to 25 °C for 2-6 hours.

The amines of formula (III), the aminopyrazoles of formulae (VII) and (VIII), and the acyl halides of formula (IX), when not commercially available, can be obtained by conventional synthetic procedures, in accordance with literature precedent, from readily accessible starting materials using standard reagents and

5 reaction conditions.

Certain of the compounds of the general formula (I), wherein R<sup>4</sup> taken together with the nitrogen atom to which it is attached completes a 4-N-(R<sup>6</sup>)-piperazinyl group and R<sup>6</sup> is as previously defined but not hydrogen, may be prepared directly from the corresponding 4-N-unsubstituted piperazine analogue, that is a compound of the general formula (I) wherein R<sup>6</sup> is hydrogen, using appropriate standard synthetic

10 procedures.

All of the above reactions are entirely conventional and appropriate reagents and conditions for their performance can readily be established by reference to standard text books and to the examples provided hereafter. Alternatives and variations will also be evident to the person skilled in the art to enable all the compounds defined by formula (I) to be prepared.

15 The biological activities of the compounds of the present invention were determined by the following test methods.

#### Phosphodiesterase activity

20 Compound affinities for cGMP and cAMP PDEs are assessed by determination of their IC<sub>50</sub> values (the concentration of inhibitor required for 50% inhibition of enzyme activity). The PDE enzymes are isolated from rabbit platelets and rat kidney, essentially by the method of W.J. Thompson et al. (Biochem., 1971 10, 311). The calcium/calmodulin (Ca/CAM)-independent cGMP PDE and the cGMP-inhibited cAMP PDE enzymes are obtained from rabbit platelets whilst, of the four major PDE enzymes of the rat kidney, the 25 Ca/CAM-dependent cGMP PDE (fraction I) is isolated. Assays are performed using a modification of the "batch" method of W.J. Thompson and M.M. Appleman (Biochem., 1979, 18, 5228). Results from these tests show that the compounds of the present invention are potent and selective inhibitors of both cGMP PDEs.

30 Platelet anti-aggregatory activity

This is assessed by the determination of a compound's ability to inhibit platelet aggregation *in vitro* induced by platelet activating factor (PAF), and to potentiate the platelet antiaggregatory action *in vitro* of activators of guanylate cyclase such as nitroprusside and EDRF. Washed platelets are prepared essentially 35 by the method of J.F. Mustard et al. (Methods in Enzymol., 1989, 169, 3) and aggregation is determined using standard turbidimetric techniques as described by G.V.R. Born, J. Physiol. (Lond), 1962, 162, 67P.

#### Antihypertensive activity

40 This is assessed following intravenous or oral administration of a compound to spontaneously hypertensive rats. Blood pressure is recorded *via* a cannula implanted in the carotid artery of either conscious or anaesthetised animals.

For administration to man in the curative or prophylactic treatment of angina, hypertension or congestive heart failure, oral dosages of the compounds will generally be in the range of from 4-800 mg 45 daily for an average adult patient (70 kg). Thus for a typical adult patient, individual tablets or capsules contain from 2-400 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per day. Dosages for intravenous, buccal or sublingual administration will typically be within the range of from 1-400 mg per single dose as required. In practice the physician will determine the actual dosing regimen which will be most suitable for an individual 50 patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case but there can be individual instances in which higher or lower dosage ranges may be merited, and such are within the scope of this invention.

For human use, the compounds of the formula (I) can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of 55 administration and standard pharmaceutical practice. For example, they may be administered orally, buccally or sublingually, in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. The compounds may also be injected parenterally, for example intra-

venously, intramuscularly, subcutaneously or intracoronarily. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or glucose to make the solution isotonic with blood.

Thus the invention provides a pharmaceutical composition comprising a compound of the formula (I), or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.

The invention also provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in medicine, particularly for the treatment of angina, hypertension, heart failure or atherosclerosis.

The invention further provides the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of stable, unstable and variant (Prinzmetal) angina, hypertension, congestive heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency e.g. post-PTCA, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma, or diseases characterised by disorders of gut motility, e.g. IBS.

The invention also includes any novel intermediates disclosed herein such as those of formulae (II) and (IV).

The preparation of the compounds of the invention will now be more particularly illustrated by reference to the following experimental Examples. The purity of the compounds was routinely monitored by thin layer chromatography (TLC) using Merck Kieselgel 60 F<sub>254</sub> plates. <sup>1</sup>H-Nuclear magnetic resonance spectra were recorded using a Nicolet QE-300 spectrometer and were in all cases consistent with the proposed structures.

20

#### EXAMPLE 1

##### 1-Methyl-3-n-propylpyrazole-5-carboxylic acid ethyl ester

25 A mixture of 3-n-propylpyrazole-5-carboxylic acid ethyl ester (24.1 g, 0.132 mol) (prepared by the method of Chem. Pharm. Bull., 1984, 32, 1568) and dimethyl sulphate (16.8 g, 0.133 mol) were heated to 90 °C for 2.5 hours. The mixture was dissolved in dichloromethane and the solution washed with sodium carbonate solution. The organic phase was separated, dried ( $MgSO_4$ ) and evaporated under vacuum to give a solid. Chromatography on silica gel (300 g), eluting with dichloromethane gave the product as a colourless oil (20.4 g, 79%). Rf 0.8 (silica; dichloromethane, methanol, acetic acid; 80:20:1).

#### EXAMPLE 2

##### 1-Methyl-3-n-propylpyrazole-5-carboxylic acid

35

1-Methyl-3-n-propylpyrazole-5-carboxylic acid ethyl ester (20.2 g, 0.10 mol) was suspended in 6N aqueous sodium hydroxide solution (50 ml, 0.30 mol). The mixture was heated to 80 °C for 2 hours then diluted with water (50 ml) and acidified with concentrated hydrochloric acid (25 ml). Filtration gave the carboxylic acid as pale brown crystals (12.3 g, 71%), m.p. 150-154 °C. Found: C, 56.99; H, 7.25; N, 16.90. C<sub>8</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> requires C, 57.13; H, 7.19; N, 16.66%.

#### EXAMPLE 3

##### 1-Methyl-4-nitro-3-n-propylpyrazole-5-carboxylic acid

45

1-Methyl-3-n-propylpyrazole-5-carboxylic acid (12.1 g, 0.072 mol) was added portionwise to a mixture of oleum (13 ml) and fuming nitric acid (11 ml), keeping the temperature below 60 °C. After the addition, the mixture was heated at 60 °C overnight and then cooled to room temperature before being poured onto ice. Filtration of the precipitate gave the nitropyrazole as a white solid (11.5 g, 75%), m.p. 124-127 °C. Found: C, 45.43; H, 5.22; N, 19.42. C<sub>8</sub>H<sub>11</sub>N<sub>3</sub>O<sub>4</sub> requires C, 45.57; H, 5.20; N, 19.71%.

#### EXAMPLE 4

##### 1-Methyl-4-nitro-3-n-propylpyrazole-5-carboxamide

55

1-Methyl-4-nitro-3-n-propylpyrazole-5-carboxylic acid (11.3 g, 0.053 mol) was added to thionyl chloride (50 ml) and the resulting mixture heated under reflux for 3 hours. The reaction mixture was then cooled and excess thionyl chloride removed by evaporation under vacuum. The oily residue was dissolved in acetone

(50 ml) and the solution cautiously added to a mixture of ice (50 g) and concentrated aqueous ammonium hydroxide solution (50 ml). The precipitate was collected by filtration to provide the pyrazolecarboxamide as a pale yellow solid (8.77 g, 78%), m.p. 141-143 °C. Found: C,45.22; H,5.71; N,26.12.  $C_8H_{12}N_4O_3$  requires C,45.28; H,5.70; N,26.40%.

5

#### EXAMPLE 5

##### 4-Amino-1-methyl-3-n-propylpyrazole-5-carboxamide

10 1-Methyl-4-nito-3-n-propylpyrazole-5-carboxamide (3.45 g, 16.2 mmol) and stannous chloride dihydrate (18.4 g, 81 mmol) were suspended in ethanol and the mixture heated under reflux for 2 hours. The resulting solution was cooled to room temperature, basified to pH 9 by the addition of 2N aqueous sodium hydroxide solution and extracted with dichloromethane (3 x 150 ml). The organic extracts were combined, dried ( $MgSO_4$ ) and evaporated under vacuum. Trituration of the residue with ether gave the aminopyrazole as an off-white solid (2.77 g, 94%), m.p. 98-101 °C. Found: C,52.84; H,7.81; N,30.38.  $C_8H_{14}N_4O$  requires C,52.73; H,7.74; N,30.75%.

#### EXAMPLE 6

##### 4-(2-Ethoxybenzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide

20 A solution of 2-ethoxybenzoyl chloride (6.1 g, 33.0 mmol) in dichloromethane (50 ml) was added to a stirred solution of 4-amino-1-methyl-3-n-propylpyrazole-5-carboxamide (3.0 g, 16.4 mmol), 4-dimethylaminopyridine (0.02 g, 0.164 mmol) and triethylamine (3.34 g, 33.0 mmol) in dichloromethane (50 ml) at 0 °C. The resulting mixture was allowed to warm to room temperature and stirred for a further 2 hours. The solvent was evaporated under vacuum, the residue dissolved in a 19:1 mixture of dichloromethane and methanol (250 ml), and then the solution washed with 1N hydrochloric acid (100 ml), dried ( $MgSO_4$ ) and evaporated under vacuum. The crude material was chromatographed on silica gel (200 g), eluting with a 97:3 mixture of dichloromethane and methanol, to give a pink solid; crystallisation from ethyl acetate-hexane gave the pyrazole-5-carboxamide as a pale pink solid (2.2 g, 40%), m.p. 153-155 °C. Found: C,61.66; H,6.77; N,16.95.  $C_{17}H_{22}N_4O_3$  requires C,61.80; H,6.71; N,16.96%.

#### EXAMPLE 7

##### 5-(2-Ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

35 4-(2-Ethoxybenzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide (223 g, 0.676 mol) was added portionwise to a solution of sodium hydroxide (54 g, 1.35 mol) and 30% hydrogen peroxide solution (224 ml) in water (2000 ml). Ethanol (700 ml) was added and the resulting mixture heated under reflux for 2.5 hours, 40 cooled, then evaporated under vacuum. The resulting solid was treated with 2N hydrochloric acid (380 ml), with external cooling, and the mixture was extracted with dichloromethane (1 x 700 ml, 3 x 200 ml). The combined organic extracts were washed successively with saturated aqueous sodium carbonate solution (3 x 400 ml) and brine (300 ml), then dried ( $Na_2SO_4$ ) and evaporated under vacuum.

45 Chromatography of the residue on silica gel (1000 g), using a methanol in dichloromethane elution gradient (0-1%), followed by trituration of the crude product with ether (300 ml), gave the title compound as a colourless solid (152.2 g, 72%), m.p. 143-146 °C. Found: C,65.56; H,6.44; N,18.14.  $C_{17}H_{20}N_4O_2$  requires C,65.36; H,6.45; N,17.94%.

#### EXAMPLE 8

##### 5-(5-Chlorosulphonyl-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

50 5-(2-Ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (10.0 g, 32.1 mmol) was added portionwise to chlorosulphonic acid (20 ml) at 0 °C under a nitrogen atmosphere. After 55 being stirred overnight, the reaction solution was cautiously added to ice-water (150 ml) and the aqueous mixture extracted with a 9:1 mixture of dichloromethane and methanol (4 x 100 ml). The combined extracts were dried ( $Na_2SO_4$ ) and evaporated under vacuum to give the required sulphonyl chloride as a white solid (12.8 g, 97%), m.p. 179-181 °C. Found: C,50.07; H,4.71; N,13.29.  $C_{17}H_{19}ClN_4O_4S$  requires C,49.70; H,4.66;

N,13.64%.

EXAMPLE 9

5 5-[2-Ethoxy-5-(4-carbamoylpiperidinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one


10 4-Carbamoylpiperidine (703 mg, 5.50 mmol) was added to a stirred suspension of 5-(5-chlorosulphonyl-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (750 mg, 1.80 mmol) in ethanol (50 ml) at room temperature. The resulting mixture was stirred for 4 days before removing the solvent by evaporation under vacuum. The residue was dissolved in a 9:1 mixture of dichloromethane and methanol (100 ml) and the solution washed with saturated aqueous sodium carbonate solution (100 ml). The aqueous phase was further extracted with dichloromethane-methanol mixtures (3 x 100 ml) and all the organic fractions were combined, dried ( $\text{MgSO}_4$ ) and evaporated under vacuum to give a solid. Crystallisation from a mixture of methanol-dimethylformamide gave the title sulphonamide as an off-white solid (446 mg, 49%), m.p. 274-276 °C. Found: C,55.36; H,6.01; N,16.65.  $\text{C}_{23}\text{H}_{29}\text{N}_6\text{O}_5\text{S}$  requires C,55.08; H,5.83; N,16.75%.

EXAMPLES 10-15

20

The following compounds were prepared by the procedure of Example 9 using the appropriate amine.

25



30




35

40

45

50

55

Example		% yield	m.p. (°C)	Analysis %		
				(Theoretical in brackets)		
		C	H	N		
10		51	161-162	54.82 (54.77)	6.13 6.13	17.95 18.25
11		79	194-196	54.63 (54.75)	6.47 6.39	16.50 16.65
12		88	187-189	55.61 (55.68)	6.23 6.37	17.74 17.71




35

40

45

50

55

5	13		21	187-188	57.48 (57.35)	6.74 6.82	16.47 16.72)
10	14		74	209-212	57.64 (57.35)	6.66 6.82	16.81 16.72)
15	15		18	229-230	51.25 (50.85)	5.56 5.63	18.92 18.87)

EXAMPLE 16

5-{2-Ethoxy-5-[4-(methylthioimidoyl)piperazinylsulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one hydroiodide

A mixture of 5-[2-ethoxy-5-(4-thiocarbamoylpiperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (0.78 g, 1.5 mmol), methyl iodide (426 mg, 3.0 mmol) and methanol (20 ml) was stirred under reflux for 2 hours, then allowed to cool. The resulting white solid was removed by filtration and crystallised from ethyl acetate-methanol to give the title compound as colourless crystals (0.70 g, 71%), m.p. 227-228 °C. Found: C,41.43; H,4.79; N,14.42. C<sub>23</sub>H<sub>31</sub>N<sub>7</sub>O<sub>4</sub>S<sub>2</sub>;HI requires C,41.75; H,4.88; N,14.82%.

EXAMPLE 17

5-{2-Ethoxy-5-[4-(methylamidino)piperazinylsulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one hydroiodide

5-{2-Ethoxy-5-[4-(methylthioimidoyl)piperazinylsulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one hydroiodide (0.5 g, 0.75 mmol) was added to a 33% solution of methylamine in ethanol (20 ml) and the mixture stirred at room temperature for 18 hours. The solution was evaporated under vacuum and the residue triturated with ether. Chromatography of the resulting solid on silica gel (10 g), using a methanol in dichloromethane elution gradient (0-4%), followed by trituration of the crude product with ether, gave a light brown powder. Crystallisation from ethyl acetate-methanol gave the title compound as colourless crystals (112 mg, 23%), m.p. 253-255 °C. Found: C,42.90; H,5.09; N,17.41. C<sub>23</sub>H<sub>32</sub>N<sub>8</sub>O<sub>4</sub>S; HI requires C,42.86; H,5.16; N,17.39%.

EXAMPLE 181-Methyl-4-(2-n-propoxybenzamido)-3-n-propylpyrazole-5-carboxamide

5 This amide was prepared from 2-n-propoxybenzoyl chloride following the procedure described in Example 6 and was obtained as a pink solid (63%), m.p. 148-149 °C. Found: C,62.97; H,7.00; N,16.29. C<sub>18</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub> requires C,62.77; H,7.02; N,16.27%.

EXAMPLE 191-Methyl-5-(2-n-propoxyphenyl)-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

10 1-Methyl-4-(2-n-propoxybenzamido)-3-n-propylpyrazole-5-carboxamide (0.34 g, 0.99 mmol) was added to a stirred mixture of 30% hydrogen peroxide solution (1.0 ml), potassium carbonate (0.54 g, 3.92 mmol), water (10 ml) and ethanol (5 ml). The mixture was heated under reflux for 38 hours and then evaporated under vacuum. The residue was suspended in water (20 ml), then the mixture acidified with 2N hydrochloric acid and extracted with dichloromethane (3 x 20 ml). The extracts are combined, dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated under vacuum. The resulting residue was chromatographed on silica gel (6 g), using a methanol in dichloromethane elution gradient (0.0-1.0%), to give an oil, successive trituration of which with ether gave  
15 the required product as a white solid (0.19 g, 59%), m.p. 111-114 °C. Found: C,66.26; H,6.92; N,17.15. C<sub>18</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> requires C,66.23; H,6.80; N,17.17%.

EXAMPLE 205-(5-Chlorosulphonyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

25 This sulphonyl chloride was prepared from 5-(2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one following the procedure of Example 8 and was obtained as a white solid (92%). Found: C,51.26; H,5.02; N,12.90. C<sub>18</sub>H<sub>21</sub>CIN<sub>4</sub>O<sub>4</sub>S requires C,50.88; H,4.98; N,13.19%.

EXAMPLE 211-Methyl-5-[5-(piperazinylsulphonyl)-2-n-propoxyphenyl]-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

30 35 This sulphonamide was prepared from piperazine and 5-(5-chlorosulphonyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one following the procedure of Example 9 and was obtained as a white solid (70%), m.p. 185-186 °C. Found: C,56.17; H,6.38; N,17.65. C<sub>22</sub>H<sub>30</sub>N<sub>6</sub>O<sub>4</sub>S requires C,55.67; H,6.37; N,17.71%.

EXAMPLE 225-[5-(4-(2-Hydroxyethyl)piperazinylsulphonyl)-2-n-propoxyphenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

40 45 This sulphonamide was prepared from N-(2-hydroxyethyl)piperazine and 5-(5-chlorosulphonyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one following the procedure of Example 9 and was obtained as colourless needles (66%), m.p. 158-159 °C. Found: C,55.83; H,6.58; N,16.13. C<sub>24</sub>H<sub>34</sub>N<sub>6</sub>O<sub>5</sub>S requires C,55.58; H,6.61; N,16.20%.

EXAMPLE 234-(2-Allyloxybenzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide

50 55 A solution of 2-allyloxybenzoyl chloride (3.93 g, 0.02 mol) in dichloromethane (20 ml) was added dropwise to a stirred, partial solution of 4-amino-1-methyl-3-n-propylpyrazole-5-carboxamide (3.64 g, 0.02 mol) in pyridine (50 ml), and the resulting mixture stirred at room temperature overnight in a dry atmosphere. The solvent was evaporated under vacuum and the residue partitioned between dich-

loromethane (50 ml) and saturated aqueous sodium carbonate solution (50 ml). The organic layer was separated and the aqueous layer exhaustively extracted with further dichloromethane. The combined organic solutions were washed with 2M HCl (3 x 30 ml), then brine (1 x 30 ml), and dried ( $\text{Na}_2\text{SO}_4$ ). After filtration and evaporation under vacuum of the filtrate, the crude product was crystallised from ethyl acetate to give the title compound (4.525 g, 66%), m.p. 132-134 °C. Found: C,63.49; H,6.42; N,16.33.  $\text{C}_{18}\text{H}_{22}\text{N}_4\text{O}_3$  requires C,63.14; H,6.48; N,16.36%.

#### EXAMPLE 24

10 5-(2-Allyloxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A mixture of 4-(2-allyloxybenzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide (1.2 g, 0.0035 mol), sodium hydroxide (0.70 g, 0.018 mol), water (34 ml) and ethanol (8 ml) was refluxed for 5 hours. After cooling, the solution was exhaustively extracted with ethyl acetate. The combined extracts were washed with brine (30 ml), dried ( $\text{Na}_2\text{SO}_4$ ), filtered and the solvent evaporated under vacuum to give a crude product which was crystallised from ethyl acetate/hexane to afford the title compound (0.476 g, 37%), m.p. 116-119 °C. Found: C,67.00; H,6.21; N,17.23.  $\text{C}_{18}\text{H}_{20}\text{N}_4\text{O}_2$  requires C,66.65; H,6.21; N,17.27%.

#### EXAMPLE 25

20 5-(2-Hydroxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A mixture of 5-(2-allyloxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (0.25 g, 0.0008 mol), phenol (0.145 g, 0.0015 mol), piperidine (0.131 g, 0.0015 mol) and tetrakis(triphenylphosphine)palladium(0) (0.046 g, 0.00004 mol) in absolute ethanol (5 ml) was refluxed overnight under nitrogen. The mixture was allowed to cool, the solvent evaporated under vacuum and the residue dissolved in ethyl acetate (40 ml). This solution was washed with water (3 x 10 ml), 1M HCl (3 x 10 ml) and brine (1 x 10 ml). After drying ( $\text{Na}_2\text{SO}_4$ ) and filtration, the filtrate was evaporated under vacuum to give the crude product. The title phenol (0.021 g, 10%) was obtained after trituration with diethyl ether and crystallisation from ethyl acetate/pentane, m.p. 233-238 °C. Found: C,63.17; H,5.65; N,19.52.  $\text{C}_{15}\text{H}_{16}\text{N}_4\text{O}_2$  requires C,63.36; H,5.67; N,19.71%.

#### EXAMPLE 26

35 5-(5-Chlorosulphonyl-2-hydroxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5-(2-Hydroxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (0.239 g, 0.00084 mol) was added, in portions, to stirred chlorosulphonic acid (3 ml) cooled to 0 °C under a nitrogen atmosphere, and the resulting deep red solution stirred at room temperature for 18 hours. The reaction mixture was then added dropwise, with care, to stirred ice/water to give a brown solid. The latter mixture was extracted with dichloromethane (3 x 30 ml), the combined extracts dried ( $\text{Na}_2\text{SO}_4$ ) and filtered, and the filtrate evaporated under vacuum to give a brown solid (0.24 g, 75%), used in the next step without further purification; Rf 0.3 (silica; dichloromethane, methanol; 95:5).

45 EXAMPLE 27

5-[2-Hydroxy-5-(4-methylpiperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

50 A solution of 5-(5-chlorosulphonyl-2-hydroxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (0.235 g, 0.0006 mol) and N-methylpiperazine (0.5 ml, 0.0045 mol) in ethanol (40 ml) was stirred at room temperature for 18 hours. The solution was evaporated under vacuum and the residue partitioned between ethyl acetate (40 ml) and water (40 ml). The fine precipitate was filtered off, washed with water then ethyl acetate, and crystallised from ethyl acetate/DMF to give the title compound as an off-white powder (0.260 g, 49%), m.p. 283-284 °C. Found: C,53.53; H,5.89; N,18.40.  $\text{C}_{20}\text{H}_{26}\text{N}_6\text{O}_4\text{S}$  requires C,53.80; H,5.87; N,18.82%.

EXAMPLE 285-[2-Allyloxy-5-(4-methylpiperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5      Allyl bromide (0.02 ml, 0.00023 mol) was added to a stirred suspension of 5-[2-hydroxy-5-(4-methylpiperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (0.103 g, 0.00023 mol) and potassium carbonate (0.032 g, 0.00023 mol) in 2-butanone (10 ml) and the mixture heated under reflux for 8 hours. After cooling, the reaction mixture was evaporated under vacuum and the residue  
 10 suspended in water (20 ml). The aqueous suspension was extracted with ethyl acetate (3 x 20 ml), the combined extracts dried ( $\text{Na}_2\text{SO}_4$ ) and, after filtration, evaporated under vacuum to give an oil. Column chromatography on silica gel (2 g) using a methanol in dichloromethane elution gradient (0-3%), followed by evaporation under vacuum of appropriate fractions, gave a semi-solid which was dissolved in acetone; evaporation under vacuum of the solution gave the title compound (0.011 g, 10%), m.p. 151-153 °C, Rf 0.5  
 15 (silica; dichloromethane, methanol; 95:5), m/e 487 ( $M^+ + 1$ ).

EXAMPLE 294-(2-Ethoxybenzamido)-1,3-dimethylpyrazole-5-carboxamide

20     This amide was prepared from 4-amino-1,3-dimethylpyrazole-5-carboxamide (prepared by the method of J. Med. Chem., 1987, 30, 91), following the procedure of Example 6, and was obtained as a white solid (81%), m.p. 178-181 °C. Found: C, 59.89; H, 6.05; N, 18.44.  $\text{C}_{15}\text{H}_{18}\text{N}_4\text{O}_3$  requires C, 59.59; H, 6.00; N, 18.53%.

EXAMPLE 305-(2-Ethoxyphenyl)-1,3-dimethyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

25     4-(2-Ethoxybenzamido)-1,3-dimethylpyrazole-5-carboxamide (1.6 g, 5.29 mmol) was added to poly-  
 30 phosphoric acid (50 g) and the mixture heated to 140 °C for 6 hours. The solution was cooled, poured into ice-water (100 ml), and then the mixture was basified with 10% aqueous sodium hydroxide solution and extracted with dichloromethane (3 x 100 ml). The organic extracts were combined, dried ( $\text{MgSO}_4$ ) and evaporated under vacuum. The residue was chromatographed on silica gel eluting with a 97:3 mixture of dichloromethane and methanol. Crystallisation of the crude product from aqueous ethanol gave the title  
 35 compound as a colourless solid, m.p. 201-204 °C. Found: C, 63.43; H, 5.57; N, 19.35.  $\text{C}_{15}\text{H}_{16}\text{N}_4\text{O}_2$  requires C, 63.36; H, 5.67; N, 19.71%.

EXAMPLE 315-(5-Chorosulphonyl-2-ethoxyphenyl)-1,3-dimethyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

40     This sulphonyl chloride was prepared from 5-(2-ethoxyphenyl)-1,3-dimethyl-1,6-dihydro-7H-pyrazolo-  
 [4,3-d]pyrimidin-7-one, following the procedure of Example 8, and was obtained in quantitative yield as a white solid. Rf 0.3 (silica:ether). It was used without further purification.


EXAMPLES 32-34

45     The following compounds were prepared from 5-(5-chlorosulphonyl-2-ethoxyphenyl)-1,3-dimethyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one and the appropriate amine following the procedure of Example 9.

50

55

5



10

15

Example		% yield	m.p. (°C)	Analysis %		
				(Theoretical in brackets)		
C	H	N				
32		68	225-226	53.88 (53.79)	5.81 5.87	18.42 (18.82)
33		68	240-242	53.07 (52.76)	5.77 5.59	19.27 (19.43)
34		62	228-229	53.23 (52.93)	5.87 5.92	17.72 (17.63)

50

EXAMPLE 354-Nitro-3-n-propylpyrazole-5-carboxylic acid

55

3-n-Propylpyrazole-5-carboxylic acid (prepared by the method of Chem. Pharm. Bull. 1984, 32, 1568), was nitrated following the procedure of Example 3, to give the title compound as a colourless solid (75%), m.p. 169-173 °C. Found: C,42.35; H,4.56; N,21.07. C<sub>7</sub>H<sub>9</sub>N<sub>3</sub>O<sub>4</sub> requires C,42.21; H,4.55; N,21.10%.

EXAMPLE 364-Nitro-3-n-propylpyrazole-5-carboxamide

5 A mixture of 4-nitro-3-n-propylpyrazole-5-carboxylic acid (7.8 g, 39.2 mmol) and thionyl chloride (35 ml) was heated under reflux for 3 hours. The solvent was removed by evaporation under vacuum and the solid residue was added portionwise to aqueous ammonium hydroxide solution (40 ml) at 0 °C. The mixture was then diluted with water (60 ml) and extracted with a 9:1 mixture of dichloromethane and methanol (3 x 100 ml). The organic fractions were combined, dried ( $\text{MgSO}_4$ ) and evaporated under vacuum, and the residue 10 crystallised from ethanol to give the carboxamide as a colourless solid (1.0 g, 13%), m.p. 202-206 °C. Found: C,42.35; H,5.01; N,28.38.  $\text{C}_7\text{H}_{10}\text{N}_4\text{O}_3$  requires C,42.42; H,5.09; N,28.27%.

EXAMPLE 374-Amino-3-n-propylpyrazole-5-carboxamide

15 A solution of 4-nitro-3-n-propylpyrazole-5-carboxamide (198 mg, 1.0 mmol) in methanol (5 ml) was added dropwise to a mixture of sodium borohydride (113 mg, 2.97 mmol), 10% palladium on carbon (5 mg) and water (3 ml). The mixture was stirred at room temperature for 3 hours, filtered and the solvent removed 20 by evaporation under vacuum. Crystallisation of the residue from ethyl acetate-methanol gave the title compound as an off-white solid (61 mg, 36%), m.p. 196-201 °C. Rf 0.4 (silica; dichloromethane, methanol, ammonium hydroxide; 90:10:1). Found: C,48.96; H,6.98; N,32.08.  $\text{C}_7\text{H}_{12}\text{N}_4\text{O}$  requires C,49.98; H,7.19; N,33.31%.

EXAMPLE 384-(2-Ethoxybenzamido)-3-n-propylpyrazole-5-carboxamide

25 The title amide was prepared from 4-amino-3-n-propylpyrazole-5-carboxamide following the procedure of Example 6, and was obtained as a white solid (64%), m.p. 209-211 °C. Found: C,60.73; H,6.41; N,17.80.  $\text{C}_{16}\text{H}_{20}\text{N}_4\text{O}_3$  requires C,60.74; H,6.37; N,17.71%.

EXAMPLE 395-(2-Ethoxyphenyl)-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

35 The title compound was prepared from 4-(2-ethoxybenzamido)-3-n-propyl-pyrazole-5-carboxamide following the procedure of Example 30 and was obtained as a white solid (16%), m.p. 199-201 °C. Found: C,64.44; H,6.19; N,18.44%.  $\text{C}_{16}\text{H}_{18}\text{N}_4\text{O}_2$  requires C,64.41; H,6.08; N,18.78%.

40

EXAMPLE 405-(5-Chlorosulphonyl-2-ethoxyphenyl)-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

45 The title sulphonyl chloride was prepared from 5-(2-ethoxyphenyl)3-n-propyl-1,6-dihydro-7H-pyrazolo-[4,3-d]pyrimidin-7-one following the procedure of Example 8 and was obtained as a white solid (78%). Rf 0.25 (silica;ether).

It was used without further purification.

EXAMPLE 415-[2-Ethoxy-5-(4-methylpiperazinyl)sulphonylphenyl]-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

55 The title sulphonamide was prepared from 5-(5-chlorosulphonyl-2-ethoxyphenyl)-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one following the procedure of Example 9 and was obtained as a white solid (70%), m.p. 236-239 °C. Found: C,54.84; H,6.27; N,18.10.  $\text{C}_{21}\text{H}_{28}\text{N}_6\text{O}_4\text{S}$  requires C,54.76; H,6.13; N,18.25%.

EXAMPLE 423-Bromomethyl-5-chloro-1-methyl-4-nitropyrazole

5 N-Bromosuccinimide (10.7 g, 60.0 mmol) was added to a solution of 5-chloro-1,3-dimethyl-4-nitropyrazole (8.78 g, 50.0 mmol) in carbon tetrachloride (100 ml) and the solution was heated under reflux whilst being irradiated with visible light (150 W tungsten lamp) for 3 days. At intervals throughout the reaction, quantities of benzoyl peroxide (6 x 50 mg) were added. The solvent was removed by evaporation under vacuum and the residue chromatographed on silica gel eluting with a 1:1 mixture of dichloromethane and hexane to give the bromide as an off-white solid (8.0 g, 63%), m.p. 80-82 °C. Found: C,23.95; H,2.05; N,16.31.  $C_5H_5BrClN_3O_2$  requires C,23.60; H,1.98; N,16.51%.

EXAMPLE 435-Chloro-3-methoxymethyl-1-methyl-4-nitropyrazole

15 A solution of 3-bromomethyl-5-chloro-1-methyl-4-nitropyrazole (5.0 g, 19.6 mmol) in methanol (50 ml) was treated with silver nitrate (5.75 g, 33.8 mmol) and the mixture heated under reflux for 2 hours. The cooled reaction mixture was filtered and the filtrate evaporated under vacuum. The residue was partitioned between ethyl acetate (100 ml) and water (50 ml) and the aqueous phase extracted with a further quantity of ethyl acetate (50 ml). The organic extracts were combined, dried ( $MgSO_4$ ) and evaporated under vacuum. Chromatography on silica gel, eluting with a 97:3 mixture of dichloromethane and methanol, gave the title pyrazole as a white solid (1.6 g, 40%), m.p. 59-63 °C. Found: C,34.65; H,3.83; N,20.05.  $C_6H_8ClN_3O_3$  requires C,35.05; H,3.92; N,20.44%.

25

EXAMPLE 445-Cyano-3-methoxymethyl-1-methyl-4-nitropyrazole

30 A solution of 5-chloro-3-methoxymethyl-1-methyl-4-nitropyrazole (205 mg, 1.0 mmol), potassium cyanide (130 mg, 2.0 mmol) and 18-crown-6 (10 mg) in acetonitrile (2 ml) was heated under reflux overnight. The solvent was evaporated under vacuum and the residue partitioned between ethyl acetate (20 ml) and water (20 ml). The organic phase was separated, dried ( $MgSO_4$ ) and evaporated under vacuum, then the residue chromatographed on silica gel eluting with a 1:1 mixture of ethyl acetate and pentane. Trituration of the crude product with ether provided a yellow solid (38 mg, 19%), m.p. 48-50 °C. Found: C,42.89; H,4.15; N,28.78.  $C_7H_8N_4O_3$  requires C,42.86; H,4.11; N,28.56%.

EXAMPLE 454-Amino-5-cyano-3-methoxymethyl-1-methylpyrazole

40 The title compound was prepared from 5-cyano-3-methoxymethyl-1-methyl-4-nitropyrazole following the procedure of Example 5 and was obtained as an off-white solid (68%), m.p. 82-84 °C. Found: C,50.81; H,6.13; N,33.94.  $C_7H_{10}N_4O$  requires C,50.59; H,6.07; N,33.72%

45

EXAMPLE 465-Cyano-4-(2-ethoxybenzamido)-3-methoxymethyl-1-methylpyrazole

50 The title compound was prepared from 4-amino-5-cyano-3-methoxymethyl-1-methylpyrazole following the procedure of Example 6 and was obtained as an off-white solid (61%), m.p. 103-105 °C. Found: C,61.21; H,5.98; N,17.80.  $C_{16}H_{18}N_4O_3$  requires C,61.13; H,5.77; N,17.83%.

55

EXAMPLE 475-(2-Ethoxyphenyl)-3-methoxymethyl-1-methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5 The title compound was prepared from 5-cyano-4-(2-ethoxybenzamido)-3-methoxymethyl-1-methyl-pyrazole following the procedure of Example 7, via *in situ* generation of the 5-primary amide derivative, and was obtained as a white solid (38%), m.p. 160-161 °C. Found: C,61.35; H,5.75; N,17.98. C<sub>16</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub> requires C,61.13; H,5.77; N,17.83%.

EXAMPLE 483-Methoxymethyl-1-methyl-5-[5-(4-methylpiperazinylsulphonyl)-2-ethoxyphenyl]-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

15 5-(2-Ethoxyphenyl)-3-methoxymethyl-1-methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (470 mg, 1.50 mmol) was dissolved in chlorosulphonic acid (3 ml) at 0 °C. The solution was stirred at room temperature for 2 hours, then cautiously added to ice-water (50 ml). The resulting solution was neutralized with saturated sodium carbonate solution, then extracted with a 20:1 mixture of dichloromethane and methanol (2 x 50 ml). The combined organic extracts were evaporated under vacuum and the residue was 20 dissolved in ethanol (5 ml) and the solution treated with N-methylpiperazine (450 mg, 4.5 mmol). After 1 hour at room temperature the solvent was evaporated under vacuum and the residue chromatographed non silica gel, eluting with a mixture of dichloromethane, methanol and aqueous ammonium hydroxide solution (90:10:1 by volume). Trituration of the crude product with ethyl acetate gave the title compound as a white solid (49 mg, 7%), m.p. 198-199 °C. Found: C,52.94; H,6.04; N,17.67. C<sub>21</sub>H<sub>28</sub>N<sub>6</sub>O<sub>5</sub>S requires C,52.93; 25 H,5.92; N,17.64%.

Also isolated following chromatography and crystallisation from a mixture of ethyl acetate and methanol was 3-hydroxymethyl-1-methyl-5-[5-(4-methylpiperazinylsulphonyl)-2-ethoxyphenyl]-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one as a white solid (51 mg, 7%), m.p. 209-210 °C. Found: C,51.94; H,5.77; N,18.05. C<sub>20</sub>H<sub>26</sub>N<sub>6</sub>O<sub>5</sub>S requires C,51.94; H,5.67; N,18.17%.

EXAMPLE 491-Ethyl-3-n-propylpyrazole-5-carboxylic acid ethyl ester

35 This pyrazole was prepared from 3-n-propylpyrazole-5-carboxylic acid ethyl ester and diethyl sulphate, following the procedure described in Example 1, and was obtained as a colourless oil (72%). Rf 0.5 (silica; ethyl acetate, hexane; 1:1).

EXAMPLE 501-Ethyl-3-n-propylpyrazole-5-carboxylic acid

This carboxylic acid was prepared from 1-ethyl-3-n-propylpyrazole-5-carboxylic acid ethyl ester, following the procedure described in Example 2, and was obtained as a pale brown solid (89%), m.p. 73-77 °C. 45 Found C, 58.62; H,7.69; N,15.23. C<sub>9</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> requires C,59.32; H,7.74; N,15.37%.

EXAMPLE 511-Ethyl-4-nitro-3-n-propylpyrazole-5-carboxylic acid

50 The title compound was prepared from 1-ethyl-3-n-propylpyrazole-5-carboxylic acid, following the procedure described in Example 3, and was obtained as a colourless solid (96%), m.p. 120-123 °C. Found: C,47.61; H,5.81; N,18.54. C<sub>9</sub>H<sub>13</sub>N<sub>3</sub>O<sub>4</sub> requires C,47.57; H,5.77; N,18.49%.

EXAMPLE 521-Ethyl-4-nitro-3-n-propylpyrazole-5-carboxamide

5 The title amide was prepared from 1-ethyl-4-nitro-3-n-propylpyrazole-5-carboxylic acid, following the procedure described in Example 4, and was obtained as an off-white solid (86%), m.p. 119-120 °C. Found: C,47.38; H,6.18; N,24.34.  $C_9H_{14}N_4O_3$  requires C,47.78; H,6.24; N,24.77%

EXAMPLE 534-Amino-1-ethyl-3-n-propylpyrazole-5-carboxamide

10 The title compound was prepared from 1-ethyl-4-nitro-3-n-propylpyrazole-5-carboxamide, by the procedure described in Example 5, and was obtained as an off-white solid (100%), m.p. 93-97 °C. Found: C,55.17; H,8.34; N,28.93.  $C_9H_{16}N_4O$  requires C,55.08; H,8.22; N,28.55%.

EXAMPLE 544-(2-Ethoxybenzamido)-1-ethyl-3-n-propylpyrazole-5-carboxamide

20 The title amide was prepared from 4-amino-1-ethyl-3-n-propylpyrazole-5-carboxamide and 2-ethoxybenzoyl chloride, following the procedure described in Example 6, and was obtained as a colourless solid (73%), m.p. 139-141 °C. Found: C,63.03; H,7.15; N,16.50.  $C_{18}H_{24}N_4O_3$  requires C,62.77; H,7.02; N,16.27%.

EXAMPLE 555-(2-Ethoxyphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

30 The title compound was prepared from 4-(2-ethoxybenzamido)-1-ethyl-3-n-propylpyrazole-5-carboxamide following the procedure of Example 7, and was obtained as a colourless solid (46%), m.p. 112-114 °C. Found: C,66.59; H,6.85; N,17.26.  $C_{18}H_{22}N_4O_2$  requires C,66.23; H,6.79; N,17.17%.

EXAMPLE 565-(5-Chlorosulphonyl-2-ethoxyphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

40 The title compound was prepared from 5-(2-ethoxyphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one following the procedure of Example 8, and was obtained as a methylene chloride solvate (86%), m.p. 170-172 °C. Found: C,49.82; H,4.84; N,12.77.  $C_{18}H_{21}ClN_4O_4S$ ; 1/6  $CH_2Cl_2$  requires C,49.70; H,4.90; N,12.77%.

EXAMPLE 575-[2-Ethoxy-5-(4-methylpiperazinylsulphonyl)phenyl]-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

50 The title sulphonamide was prepared from 5-(5-chlorosulphonyl-2-ethoxyphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one and N-methylpiperazine following the procedure of Example 9 and was obtained as a colourless solid (43%), m.p. 160-162 °C. Found: C,57.24; H,6.17; N,16.83.  $C_{23}H_{32}N_6O_4S$  requires C,56.54; H,6.60; N,17.20%. Rf 0.35 (silica; dichloromethane, methanol; 9:1).

EXAMPLE 585-[2-Ethoxy-5-[4-(2-hydroxyethyl)piperazinylsulphonyl]phenyl]-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one


55 The title sulphonamide was prepared from 5-(5-chlorosulphonyl-2-ethoxyphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H pyrazolo[4,3-d]pyrimidin-7-one and N-(2-hydroxyethyl)piperazine following the procedure of

Example 9 and was obtained as a colourless solid (88%), m.p. 191-193 °C. Found: C, 55.74; H, 6.55; N, 15.78. C<sub>24</sub>H<sub>34</sub>N<sub>6</sub>O<sub>5</sub>S requires C, 55.58; H, 6.61; N, 16.20%.

### Claims

5    **Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE**

1. A compound of the formula:



25    wherein

R<sup>1</sup> is H, C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>3</sub>-C<sub>5</sub> cycloalkyl or C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl;

R<sup>2</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by OH, C<sub>1</sub>-C<sub>3</sub> alkoxy or C<sub>3</sub>-C<sub>6</sub> cycloalkyl, or C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl;

R<sup>3</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl or (C<sub>3</sub>-C<sub>6</sub> cycloalkyl)C<sub>1</sub>-C<sub>6</sub> alkyl;

30    R<sup>4</sup> taken together with the nitrogen atom to which it is attached completes a pyrrolidinyl, piperidino, morpholino, or 4-N-(R<sup>6</sup>)-piperazinyl group;

R<sup>5</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, NR<sup>7</sup>R<sup>8</sup>, or CONR<sup>7</sup>R<sup>8</sup>;

R<sup>6</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, (C<sub>1</sub>-C<sub>3</sub> alkoxy)C<sub>2</sub>-C<sub>6</sub> alkyl, hydroxy C<sub>2</sub>-C<sub>6</sub> alkyl, (R<sup>7</sup>R<sup>8</sup>N)C<sub>2</sub>-C<sub>6</sub> alkyl, (R<sup>7</sup>R<sup>8</sup>NCO)C<sub>1</sub>-C<sub>6</sub> alkyl, CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> or C(NH)NR<sup>7</sup>R<sup>8</sup>;

35    R<sup>7</sup> and R<sup>8</sup> are each independently H, C<sub>1</sub>-C<sub>4</sub> alkyl, (C<sub>1</sub>-C<sub>3</sub> alkoxy)C<sub>2</sub>-C<sub>4</sub> alkyl or hydroxy C<sub>2</sub>-C<sub>4</sub> alkyl;

and pharmaceutically acceptable salts thereof.

- 40    2. A compound as claimed in Claim 1 wherein R<sup>1</sup> is H, methyl or ethyl; R<sup>2</sup> is C<sub>1</sub>-C<sub>3</sub> alkyl optionally substituted by OH or methoxy; R<sup>3</sup> is C<sub>2</sub>-C<sub>3</sub> alkyl or allyl; R<sup>4</sup> taken together with the nitrogen atom to which it is attached completes a piperidino or 4-N-(R<sup>6</sup>) piperazinyl group; R<sup>5</sup> is H, NR<sup>7</sup>R<sup>8</sup> or CONR<sup>7</sup>R<sup>8</sup>; R<sup>6</sup> is H, C<sub>1</sub>-C<sub>3</sub> alkyl, hydroxy C<sub>2</sub>-C<sub>3</sub> alkyl, CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> or C(NH)NR<sup>7</sup>R<sup>8</sup>; and R<sup>7</sup> and R<sup>8</sup> are each independently H or methyl.
- 45    3. A compound as claimed in Claim 2 wherein R<sup>1</sup> is methyl; R<sup>2</sup> is n-propyl; R<sup>3</sup> is ethyl, n-propyl or allyl; R<sup>4</sup> taken together with the nitrogen atom to which it is attached completes a 4-N-(R<sup>6</sup>) piperazinyl group; R<sup>5</sup> is H; and R<sup>6</sup> is H, C<sub>1</sub>-C<sub>3</sub> alkyl or 2-hydroxyethyl.

- 50    4. A compound as claimed in Claim 3 wherein said compound is selected from:
- 5-[2-allyloxy-5-(4-methylpiperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
  - 5-[2-ethoxy-5-(piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
  - 5-[2-ethoxy-5-(4-methylpiperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
  - 5-[2-ethoxy-5-[4-(2-propyl)piperazinylsulphonyl]phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5-{2-ethoxy-5-[4-(2-hydroxyethyl)piperazinylsulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

1-methyl-5-[5-(piperazinylsulphonyl)-2-n-propoxyphenyl]-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5 and 5-{5-[4-(2-hydroxyethyl)piperazinylsulphonyl]-2-n-propoxyphenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one,  
and pharmaceutically acceptable salts thereof.

10 5. A pharmaceutical composition comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof, as claimed in any one of Claims 1 to 4, together with a pharmaceutically acceptable diluent or carrier.


15 6. A compound of the formula (I) or a pharmaceutically acceptable salt thereof, as claimed in any one of Claims 1 to 4, for use in medicine, particularly for the treatment of angina, hypertension, heart failure or atherosclerosis.

20 7. The use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, as claimed in any one of Claims 1 to 4, for the manufacture of a medicament, particularly for the treatment of angina, hypertension, heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility.

25 8. A compound of the formula:

25

30



35

wherein R<sup>1</sup> and R<sup>2</sup> are as claimed in Claim 1, R<sup>3</sup> is as claimed in Claim 1 and is also H, and Y is chloro, bromo or fluoro.

40

45

50

55

## Claims for the following Contracting State : ES

1. A process for preparing a compound of the formula:

5

10

15

20

wherein

R<sup>1</sup> is H, C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>3</sub>-C<sub>5</sub> cycloalkyl or C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl;

R<sup>2</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by OH, C<sub>1</sub>-C<sub>3</sub> alkoxy or C<sub>3</sub>-C<sub>6</sub> cycloalkyl, or C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl;

25

R<sup>3</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl or (C<sub>3</sub>-C<sub>6</sub> cycloalkyl)C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>4</sup> taken together with the nitrogen atom to which it is attached completes a pyrrolidinyl, piperidino, morpholino, or 4-N-(R<sup>6</sup>)-piperazinyl group;

30

R<sup>5</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, NR<sup>7</sup>R<sup>8</sup>, or CONR<sup>7</sup>R<sup>8</sup>;

R<sup>6</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, (C<sub>1</sub>-C<sub>3</sub> alkoxy)C<sub>2</sub>-C<sub>6</sub> alkyl, hydroxy C<sub>2</sub>-C<sub>6</sub> alkyl, (R<sup>7</sup>R<sup>8</sup>N)C<sub>2</sub>-C<sub>6</sub> alkyl, (R<sup>7</sup>R<sup>8</sup>NCO)C<sub>1</sub>-C<sub>6</sub> alkyl, CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> or C(NH)NR<sup>7</sup>R<sup>8</sup>;


R<sup>7</sup> and R<sup>8</sup> are each independently H, C<sub>1</sub>-C<sub>4</sub> alkyl, (C<sub>1</sub>-C<sub>3</sub> alkoxy)C<sub>2</sub>-C<sub>4</sub> alkyl or hydroxy C<sub>2</sub>-C<sub>4</sub> alkyl;

and pharmaceutically acceptable salts thereof, which comprises reacting a compound of the formula:

35


40

45



55

wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as previously defined and Y is chloro, bromo or fluoro, with a compound of the formula:




wherein R<sup>4</sup> and R<sup>5</sup> are as previously defined, and optionally converting the required product to a pharmaceutically acceptable salt.

2. A process as claimed in Claim 1 wherein R<sup>1</sup>, R<sup>2</sup> R<sup>4</sup> and R<sup>5</sup> are as claimed in Claim 1 and R<sup>3</sup> is H, followed by O-alkylation of the phenol and optional conversion of the required product to a pharmaceutically acceptable salt.
3. A process as claimed in Claim 1 or Claim 2 wherein R<sup>1</sup>, R<sup>4</sup> and R<sup>5</sup> are as claimed in Claim 1, and R<sup>3</sup> is as claimed in Claim 1 or Claim 2, wherein R<sup>2</sup> contains an acetyl- or benzoyl-protected hydroxy substituent, said protecting group being subsequently removed by base hydrolysis before optional conversion of the required product to a pharmaceutically acceptable salt.
4. A process as claimed in any of Claims 1 to 3 wherein R<sup>1</sup> is H, methyl or ethyl; R<sup>2</sup> is C<sub>1</sub>-C<sub>3</sub> alkyl optionally substituted by OH or methoxy; R<sup>3</sup> is C<sub>2</sub>-C<sub>3</sub> alkyl or allyl; R<sup>4</sup> taken together with the nitrogen atom to which it is attached completes a piperidino or 4-N-(R<sup>6</sup>) piperazinyl group; R<sup>5</sup> is H, NR<sup>7</sup>R<sup>8</sup> or CONR<sup>7</sup>R<sup>8</sup>; R<sup>6</sup> is H, C<sub>1</sub>-C<sub>3</sub> alkyl, hydroxy C<sub>2</sub>-C<sub>3</sub> alkyl, CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> or C(NH)NR<sup>7</sup>R<sup>8</sup>; and R<sup>7</sup> and R<sup>8</sup> are each independently H or methyl.
5. A process as claimed in Claim 4 wherein R<sup>1</sup> is methyl; R<sup>2</sup> is n-propyl; R<sup>3</sup> is ethyl, n-propyl or allyl; R<sup>4</sup> taken together with the nitrogen atom to which it is attached completes a 4-N-(R<sup>6</sup>) piperazinyl group; R<sup>5</sup> is H; and R<sup>6</sup> is H, C<sub>1</sub>-C<sub>3</sub> alkyl or 2-hydroxyethyl.
6. A process as claimed in Claim 5 wherein said compound of formula (I) produced is selected from:  
 5-[2-allyloxy-5-(4-methylpiperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;  
 5-[2-ethoxy-5-(piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;  
 5-[2-ethoxy-5-(4-methylpiperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;  
 5-[2-ethoxy-5-[4-(2-propyl)piperazinylsulphonyl]phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;  
 5-[2-ethoxy-5-[4-(2-hydroxyethyl)piperazinylsulphonyl]phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;  
 1-methyl-5-[5-(piperazinylsulphonyl)-2-n-propoxyphenyl]-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;  
 and 5-[5-[4-(2-hydroxyethyl)piperazinylsulphonyl]-2-n-propoxyphenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one,  
 and pharmaceutically acceptable salts thereof.

**40 Claims for the following Contracting State : GR**

1. A process for preparing a compound of the formula:



wherein

R<sup>1</sup> is H, C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>3</sub>-C<sub>5</sub> cycloalkyl or C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl;

R<sup>2</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted OH, C<sub>1</sub>-C<sub>3</sub> alkoxy or C<sub>3</sub>-C<sub>6</sub> cycloalkyl, or C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl;

R<sup>3</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl or (C<sub>3</sub>-C<sub>6</sub> cycloalkyl)C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>4</sup> taken together with the nitrogen atom to which it is attached completes a pyrrolidinyl, piperidino, morpholino, or 4-N-(R<sup>6</sup>)-piperazinyl group;


R<sup>5</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, NR<sup>7</sup>R<sup>8</sup>, or CONR<sup>7</sup>R<sup>8</sup>;

R<sup>6</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, (C<sub>1</sub>-C<sub>3</sub> alkoxy)C<sub>2</sub>-C<sub>6</sub> alkyl, hydroxy C<sub>2</sub>-C<sub>6</sub> alkyl, (R<sup>7</sup>R<sup>8</sup>N)C<sub>2</sub>-C<sub>6</sub> alkyl, (R<sup>7</sup>R<sup>8</sup>NCO)C<sub>1</sub>-C<sub>6</sub> alkyl, CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> or C(NH)NR<sup>7</sup>R<sup>8</sup>;


R<sup>7</sup> and R<sup>8</sup> are each independently H, C<sub>1</sub>-C<sub>4</sub> alkyl, (C<sub>1</sub>-C<sub>3</sub> alkoxy)C<sub>2</sub>-C<sub>4</sub> alkyl or hydroxy C<sub>2</sub>-C<sub>4</sub> alkyl;

and pharmaceutically acceptable salts thereof,

which comprises reacting a compound of the formula:



wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as previously defined and Y is chloro, bromo or fluoro, with a compound of the formula:



wherein R<sup>4</sup> and R<sup>5</sup> are as previously defined, and optionally converting the required product to a pharmaceutically acceptable salt.

2. A process as claimed in Claim 1 wherein R<sup>1</sup>, R<sup>2</sup> R<sup>4</sup> and R<sup>5</sup> are as claimed in Claim 1 and R<sup>3</sup> is H, followed by O-alkylation of the phenol and optional conversion of the required product to a pharmaceutically acceptable salt.
3. A process as claimed in Claim 1 or Claim 2 wherein R<sup>1</sup>, R<sup>4</sup> and R<sup>5</sup> are as claimed in Claim 1, and R<sup>3</sup> is as claimed in Claim 1 or Claim 2, wherein R<sup>2</sup> contains an acetyl- or benzoyl-protected hydroxy substituent, said protecting group being subsequently removed by base hydrolysis before optional conversion of the required product to a pharmaceutically acceptable salt.
4. A process as claimed in any of Claims 1 to 3 wherein R<sup>1</sup> is H, methyl or ethyl; R<sup>2</sup> is C<sub>1</sub>-C<sub>3</sub> alkyl optionally substituted by OH or methoxy; R<sup>3</sup> is C<sub>2</sub>-C<sub>3</sub> alkyl or allyl; R<sup>4</sup> taken together with the nitrogen atom to which it is attached completes a piperidino or 4-N-(R<sup>6</sup>) piperazinyl group; R<sup>5</sup> is H, NR<sup>7</sup>R<sup>8</sup>; R<sup>6</sup> is H, C<sub>1</sub>-C<sub>3</sub> alkyl, hydroxy C<sub>2</sub>-C<sub>3</sub> alkyl, CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> or C(NH)NR<sup>7</sup>R<sup>8</sup>; and R<sup>7</sup> and R<sup>8</sup> are each independently H or methyl.


5. A process as claimed in Claim 4 wherein R<sup>1</sup> is methyl; R<sup>2</sup> is n-propyl; R<sup>3</sup> is ethyl, n-propyl or allyl; R<sup>4</sup> taken together with the nitrogen atom to which it is attached completes a 4-N-(R<sup>6</sup>) piperazinyl group; R<sup>5</sup> is H; and R<sup>6</sup> is H, C<sub>1</sub>-C<sub>3</sub> alkyl or 2-hydroxyethyl.
- 5    6. A process as claimed in Claim 5 wherein said compound of formula (I) produced is selected from:  
 5-[2-allyloxy-5-(4-methylpiperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo-[4,3-d]pyrimidin-7-one;  
 5-[2-ethoxy-5-(piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]-pyrimidin-7-one;  
 10    5-[2-ethoxy-5-(4-methylpiperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo-[4,3-d]pyrimidin-7-one;  
 5-{2-ethoxy-5-[4-(2-propyl)piperazinylsulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;  
 15    5-{2-ethoxy-5-[4-(2-hydroxyethyl)piperazinylsulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;  
 1-methyl-5-[5-(piperazinylsulphonyl)-2-n-propoxyphenyl]-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]-pyrimidin-7-one;  
 and 5-{5-[4-(2-hydroxyethyl)piperazinylsulphonyl]-2-n-propoxyphenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one,  
 20    and pharmaceutically acceptable salts thereof.

7. A compound of the formula:

25

30

35



wherein R<sup>1</sup> and R<sup>2</sup> are as claimed in Claim 1, R<sup>3</sup> is as claimed in Claim 1 and is also H, and Y is chloro, bromo or fluoro.

40


45

50

55

**Patentansprüche****Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE****1. Verbindung der Formel:**

5




worin R<sup>1</sup> H, C<sub>1</sub>-C<sub>3</sub>-Alkyl, C<sub>3</sub>-C<sub>5</sub>-Cycloalkyl oder C<sub>1</sub>-C<sub>3</sub>-Perfluoralkyl bedeutet; R<sup>2</sup> H, C<sub>1</sub>-C<sub>6</sub>-Alkyl, gegebenenfalls substituiert durch OH, C<sub>1</sub>-C<sub>3</sub>-Alkoxy oder C<sub>3</sub>-C<sub>6</sub>-Cycloalkyl oder C<sub>1</sub>-C<sub>3</sub>-Perfluoralkyl darstellt; R<sup>3</sup> C<sub>1</sub>-C<sub>6</sub>-Alkyl, C<sub>3</sub>-C<sub>6</sub>-Alkenyl, C<sub>3</sub>-C<sub>6</sub>-Alkinyl, C<sub>3</sub>-C<sub>7</sub>-Cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-Perfluoralkyl oder (C<sub>3</sub>-C<sub>6</sub>-Cycloalkyl)-C<sub>1</sub>-C<sub>6</sub>-alkyl ist; R<sup>4</sup> zusammen mit dem Stickstoffatom, an das es gebunden ist, eine Pyrrolidinyl-, Piperidino-, Morpholino- oder 4-N-(R<sup>6</sup>)-Piperazinyl-Gruppe bildet; R<sup>5</sup> H, C<sub>1</sub>-C<sub>4</sub>-Alkyl, C<sub>1</sub>-C<sub>3</sub>-Alkoxy, NR<sup>7</sup>R<sup>8</sup> oder CONR<sup>7</sup>R<sup>8</sup> bedeutet; R<sup>6</sup> H, C<sub>1</sub>-C<sub>6</sub>-Alkyl, (C<sub>1</sub>-C<sub>3</sub>-Alkoxy)-C<sub>2</sub>-C<sub>6</sub>-alkyl, Hydroxy-C<sub>2</sub>-C<sub>6</sub>-alkyl, (R<sup>7</sup>R<sup>8</sup>N)-C<sub>2</sub>-C<sub>6</sub>-Alkyl, (R<sup>7</sup>R<sup>8</sup>NCO)-C<sub>1</sub>-C<sub>6</sub>-Alkyl, CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> oder C(NH)NR<sup>7</sup>R<sup>8</sup> darstellt; und R<sup>7</sup> und R<sup>8</sup> jeweils unabhängig H, C<sub>1</sub>-C<sub>4</sub>-Alkyl, (C<sub>1</sub>-C<sub>3</sub>-Alkoxy)-C<sub>2</sub>-C<sub>4</sub>-alkyl oder Hydroxy-C<sub>2</sub>-C<sub>4</sub>-alkyl sind; und pharmazeutisch annehmbare Salze hievon.

2. Verbindung nach Anspruch 1, worin R<sup>1</sup> H, Methyl oder Ethyl bedeutet; R<sup>2</sup> C<sub>1</sub>-C<sub>3</sub>-Alkyl, gegebenenfalls substituiert durch OH oder Methoxy, darstellt; R<sup>3</sup> C<sub>2</sub>-C<sub>3</sub>-Alkyl oder Allyl ist; R<sup>4</sup> zusammen mit dem Stickstoffatom, an das es gebunden ist, eine Piperidino- oder 4-N-(R<sup>6</sup>)-Piperazinyl-Gruppe bildet; R<sup>5</sup> H, NR<sup>7</sup>R<sup>8</sup> oder CONR<sup>7</sup>R<sup>8</sup> bedeutet; R<sup>6</sup> H, C<sub>1</sub>-C<sub>3</sub>-Alkyl, Hydroxy-C<sub>2</sub>-C<sub>3</sub>-alkyl, CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> oder C(NH)NR<sup>7</sup>R<sup>8</sup> darstellt; und R<sup>7</sup> und R<sup>8</sup> jeweils unabhängig H oder Methyl sind.

3. Verbindung nach Anspruch 2, worin R<sup>1</sup> Methyl bedeutet; R<sup>2</sup> n-Propyl darstellt; R<sup>3</sup> Ethyl, n-Propyl oder Allyl ist; R<sup>4</sup> zusammen mit dem Stickstoffatom, an das es gebunden ist, eine 4-N-(R<sup>6</sup>)-Piperazinyl-Gruppe bildet; R<sup>5</sup> H bedeutet; und R<sup>6</sup> H, C<sub>1</sub>-C<sub>3</sub>-Alkyl oder 2-Hydroxyethyl darstellt.

4. Verbindung nach Anspruch 3, wobei die Verbindung ausgewählt ist aus:  
 5-[2-Allyloxy-5-(4-methylpiperazinylsulfonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on;  
 5-[2-Ethoxy-5-(piperazinylsulfonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on;  
 5-[2-Ethoxy-5-(4-methylpiperazinylsulfonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on;  
 5-[2-Ethoxy-5-[4-(2-propyl)-piperazinylsulfonyl]-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on;  
 5-[2-Ethoxy-5-[4-(2-hydroxyethyl)-piperazinylsulfonyl]phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on;  
 1-Methyl-5-[5-(piperazinylsulfonyl)-2-n-propoxyphenyl]-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on; und  
 5-[5-[4-(2-Hydroxyethyl)-piperazinylsulfonyl]-2-n-propoxyphenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on,  
 und pharmazeutisch annehmbaren Salzen hievon.


5. Pharmazeutische Zusammensetzung, welche eine Verbindung der Formel (I) oder ein pharmazeutisch annehmbares Salz hieron nach einem der Ansprüche 1 bis 4 zusammen mit einem pharmazeutisch annehmbaren Verdünnungsmittel oder Träger umfaßt.
- 5    6. Verbindung der Formel (I) oder ein pharmazeutisch annehmbares Salz hieron nach einem der Ansprüche 1 bis 4 zur Verwendung in der Medizin, insbesondere zur Behandlung von Angina, Hypertonie, Herzversagen oder Arteriosklerose.
- 10    7. Verwendung einer Verbindung der Formel (I) oder eines pharmazeutisch annehmbaren Salzes hieron nach einem der Ansprüche 1 bis 4 bei der Herstellung eines Medikaments, insbesondere zur Behandlung von Angina, Hypertonie, Herzversagen, Arteriosklerose, Schlaganfall, peripheren Gefäßerkrankungen, Zuständen reduzierter Durchgängigkeit der Blutgefäße, chronischem Asthma, Bronchitis, allergischem Asthma, Heuschnupfen, Glaukom oder durch Störungen der Darmmotilität charakterisierten Erkrankungen.
- 15    8. Verbindung der Formel:



30    worin R<sup>1</sup> und R<sup>2</sup> wie in Anspruch 1 definiert sind, R<sup>3</sup> wie in Anspruch 1 definiert ist, und auch H bedeutet, und Y Chlor, Brom oder Fluor darstellt.

**Patentansprüche für folgenden Vertragsstaat : ES**


- 35    1. Verfahren zur Herstellung einer Verbindung der Formel:




55    worin R<sup>1</sup> H, C<sub>1</sub>-C<sub>3</sub>-Alkyl, C<sub>3</sub>-C<sub>5</sub>-Cycloalkyl oder C<sub>1</sub>-C<sub>3</sub>-Perfluoralkyl bedeutet; R<sup>2</sup> H, C<sub>1</sub>-C<sub>6</sub>-Alkyl, gegebenenfalls substituiert durch OH, C<sub>1</sub>-C<sub>3</sub>-Alkoxy oder C<sub>3</sub>-C<sub>6</sub>-Cycloalkyl oder C<sub>1</sub>-C<sub>3</sub>-Perfluoralkyl darstellt; R<sup>3</sup> C<sub>1</sub>-C<sub>6</sub>-Alkyl, C<sub>3</sub>-C<sub>6</sub>-Alkenyl, C<sub>3</sub>-C<sub>6</sub>-Alkinyl, C<sub>3</sub>-C<sub>7</sub>-Cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-Perfluoralkyl oder (C<sub>3</sub>-C<sub>6</sub>-Cycloalkyl)-C<sub>1</sub>-C<sub>6</sub>-alkyl ist; R<sup>4</sup> zusammen mit dem Stickstoffatom, an das es gebunden ist, eine

Pyrrolidinyl-, Piperidino-, Morpholino- oder 4-N-(R<sup>6</sup>)-Piperazinyl-Gruppe bildet; R<sup>5</sup> H, C<sub>1</sub>-C<sub>4</sub>-Alkyl, C<sub>1</sub>-C<sub>3</sub>-Alkoxy, NR<sup>7</sup>R<sup>8</sup> oder CONR<sup>7</sup>R<sup>8</sup> bedeutet; R<sup>6</sup> H, C<sub>1</sub>-C<sub>6</sub>-Alkyl, (C<sub>1</sub>-C<sub>3</sub>-Alkoxy)-C<sub>2</sub>-C<sub>6</sub>-alkyl, Hydroxy-C<sub>2</sub>-C<sub>6</sub>-alkyl, (R<sup>7</sup>R<sup>8</sup>N)-C<sub>2</sub>-C<sub>6</sub>-Alkyl, (R<sup>7</sup>R<sup>8</sup>NCO)-C<sub>1</sub>-C<sub>6</sub>-Alkyl, CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> oder C(NH)NR<sup>7</sup>R<sup>8</sup> darstellt; und R<sup>7</sup> und R<sup>8</sup> jeweils unabhängig H, C<sub>1</sub>-C<sub>4</sub>-Alkyl, (C<sub>1</sub>-C<sub>3</sub>-Alkoxy)-C<sub>2</sub>-C<sub>4</sub>-alkyl oder Hydroxy-C<sub>2</sub>-C<sub>4</sub>-alkyl sind; und pharmazeutisch annehmbarer Salze hievon, welches umfaßt:

5 Umsetzen einer Verbindung der Formel:



10 20 worin R<sup>1</sup>, R<sup>2</sup> und R<sup>3</sup> wie oben definiert sind, und Y Chlor, Brom oder Fluor darstellt, mit einer  
15 Verbindung der Formel:



30 30 worin R<sup>4</sup> und R<sup>5</sup> wie oben definiert sind, und gegebenenfalls Überführen des erforderlichen Produkts in  
ein pharmazeutisch annehmbares Salz.

2. Verfahren nach Anspruch 1, wobei R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> und R<sup>5</sup> wie in Anspruch 1 definiert sind, und R<sup>3</sup> H  
35 bedeutet, gefolgt von einer O-Alkylierung des Phenols und gegebenenfalls einer Überführung des  
erforderlichen Produkts in ein pharmazeutisch annehmbares Salz.
3. Verfahren nach Anspruch 1 oder Anspruch 2, wobei R<sup>1</sup>, R<sup>4</sup> und R<sup>5</sup> wie in Anspruch 1 definiert sind, R<sup>3</sup>  
40 wie in Anspruch 1 oder Anspruch 2 definiert ist, und R<sup>2</sup> einen Acetyl- oder Benzoylgeschützten  
Hydroxy-Substituenten enthält, welche Schutzgruppe anschließend durch Basenhydrolyse vor der  
gegebenenfalls durchgeföhrten Überführung des erforderlichen Produkts in ein pharmazeutisch an-  
nehmbares Salz entfernt wird.
4. Verfahren nach einem der Ansprüche 1 bis 3, wobei R<sup>1</sup> H, Methyl oder Ethyl bedeutet; R<sup>2</sup> C<sub>1</sub>-C<sub>3</sub>-Alkyl,  
45 gegebenenfalls substituiert durch OH oder Methoxy, darstellt; R<sup>3</sup> C<sub>2</sub>-C<sub>3</sub>-Alkyl oder Allyl ist; R<sup>4</sup>  
zusammen mit dem Stickstoffatom, an das es gebunden ist, eine Piperidino- oder 4-N-(R<sup>6</sup>)-Piperazinyl-  
Gruppe bildet; R<sup>5</sup> H, NR<sup>7</sup>R<sup>8</sup> oder CONR<sup>7</sup>R<sup>8</sup> bedeutet; R<sup>6</sup> H, C<sub>1</sub>-C<sub>3</sub>-Alkyl, Hydroxy-C<sub>2</sub>-C<sub>3</sub>-alkyl,  
CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> oder C(NH)NR<sup>7</sup>R<sup>8</sup> darstellt; und R<sup>7</sup> und R<sup>8</sup> jeweils unabhängig H oder Methyl  
sind.
5. Verfahren nach Anspruch 4, wobei R<sup>1</sup> Methyl bedeutet; R<sup>2</sup> n-Propyl darstellt; R<sup>3</sup> Ethyl, n-Propyl oder  
50 Allyl ist; R<sup>4</sup> zusammen mit dem Stickstoffatom, an das es gebunden ist, eine 4-N-(R<sup>6</sup>)-Piperazinyl-  
Gruppe bildet; R<sup>5</sup> H bedeutet; und R<sup>6</sup> H, C<sub>1</sub>-C<sub>3</sub>-Alkyl oder 2-Hydroxyethyl darstellt.
- 55 6. Verfahren nach Anspruch 5, bei welchem die Verbindung der Formel (I) ausgewählt wird aus:  
5-[2-Allyloxy-5-(4-methylpiperazinylsulfonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo-[4,3-d]pyrimidin-7-on;  
5-[2-Ethoxy-5-(piperazinylsulfonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]-

pyrimidin-7-on;

5-[2-Ethoxy-5-(4-methylpiperazinylsulfonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo-[4,3-d]pyrimidin-7-on;

5-[2-Ethoxy-5-[4-(2-propyl)-piperazinylsulfonyl]-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-

5 pyrazolo[4,3-d]pyrimidin-7-on;

5-[2-Ethoxy-5-[4-(2-hydroxyethyl)-piperazinylsulfonyl]phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on;

10 1-Methyl-5-[5-(piperazinylsulfonyl)-2-n-propoxypyhenyl]-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on; und

10 5-[5-[4-(2-Hydroxyethyl)-piperazinylsulfonyl]-2-n-propoxypyhenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on,


und pharmazeutisch annehmbaren Salzen hievon.

**Patentansprüche für folgenden Vertragsstaat : GR**

15

1. Verfahren zur Herstellung einer Verbindung der Formel:

20



25

30

35

worin R<sup>1</sup> H, C<sub>1</sub>-C<sub>3</sub>-Alkyl, C<sub>3</sub>-C<sub>5</sub>-Cycloalkyl oder C<sub>1</sub>-C<sub>3</sub>-Perfluoralkyl bedeutet; R<sup>2</sup> H, C<sub>1</sub>-C<sub>6</sub>-Alkyl, gegebenenfalls substituiert durch OH, C<sub>1</sub>-C<sub>3</sub>-Alkoxy oder C<sub>3</sub>-C<sub>6</sub>-Cycloalkyl oder C<sub>1</sub>-C<sub>3</sub>-Perfluoralkyl darstellt; R<sup>3</sup> C<sub>1</sub>-C<sub>6</sub>-Alkyl, C<sub>3</sub>-C<sub>6</sub>-Alkenyl, C<sub>3</sub>-C<sub>6</sub>-Alkinyl, C<sub>3</sub>-C<sub>7</sub>-Cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-Perfluoralkyl oder (C<sub>3</sub>-C<sub>6</sub>-Cycloalkyl)-C<sub>1</sub>-C<sub>6</sub>-alkyl ist; R<sup>4</sup> zusammen mit dem Stickstoffatom, an das es gebunden ist, eine Pyrrolidinyl-, Piperidino-, Morpholino- oder 4-N-(R<sup>6</sup>)-Piperazinyl-Gruppe bildet; R<sup>5</sup> H, C<sub>1</sub>-C<sub>4</sub>-Alkyl, C<sub>1</sub>-C<sub>3</sub>-Alkoxy, NR<sup>7</sup>R<sup>8</sup> oder CONR<sup>7</sup>R<sup>8</sup> bedeutet; R<sup>6</sup> H, C<sub>1</sub>-C<sub>6</sub>-Alkyl, (C<sub>1</sub>-C<sub>3</sub>-Alkoxy)-C<sub>2</sub>-C<sub>6</sub>-alkyl, Hydroxy-C<sub>2</sub>-C<sub>6</sub>-alkyl, (R<sup>7</sup>R<sup>8</sup>N)-C<sub>2</sub>-C<sub>6</sub>-Alkyl, (R<sup>7</sup>R<sup>8</sup>NCO)-C<sub>1</sub>-C<sub>6</sub>-Alkyl, CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> oder C(NH)NR<sup>7</sup>R<sup>8</sup> darstellt; und R<sup>7</sup> und R<sup>8</sup> jeweils unabhängig H, C<sub>1</sub>-C<sub>4</sub>-Alkyl, (C<sub>1</sub>-C<sub>3</sub>-Alkoxy)-C<sub>2</sub>-C<sub>4</sub>-alkyl oder Hydroxy-C<sub>2</sub>-C<sub>4</sub>-alkyl sind; und pharmazeutisch annehmbarer Salze hievon, welches umfaßt:

Umsetzen einer Verbindung der Formel:


45

50

55

worin R<sup>1</sup>, R<sup>2</sup> und R<sup>3</sup> wie oben definiert sind, und Y Chlor, Brom oder Fluor darstellt, mit einer Verbindung der Formel:

5



worin R<sup>4</sup> und R<sup>5</sup> wie oben definiert sind, und gegebenenfalls Überführen des erforderlichen Produkts in ein pharmazeutisch annehmbares Salz.

10

2. Verfahren nach Anspruch 1, wobei R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> und R<sup>5</sup> wie in Anspruch 1 definiert sind, und R<sup>3</sup> H bedeutet, gefolgt von einer O-Alkylierung des Phenols und gegebenenfalls einer Überführung des erforderlichen Produkts in ein pharmazeutisch annehmbares Salz.

15

3. Verfahren nach Anspruch 1 oder Anspruch 2, wobei R<sup>1</sup>, R<sup>4</sup> und R<sup>5</sup> wie in Anspruch 1 definiert sind, R<sup>3</sup> wie in Anspruch 1 oder Anspruch 2 definiert ist, und R<sup>2</sup> einen Acetyl- oder Benzoylgeschützten Hydroxy-Substituenten enthält, welche Schutzgruppe anschließend durch Basenhydrolyse vor der gegebenenfalls durchgeführten Überführung des erforderlichen Produkts in ein pharmazeutisch annehmbares Salz entfernt wird.

20

4. Verfahren nach einem der Ansprüche 1 bis 3, wobei R<sup>1</sup> H, Methyl oder Ethyl bedeutet; R<sup>2</sup> C<sub>1</sub>-C<sub>3</sub>-Alkyl, gegebenenfalls substituiert durch OH oder Methoxy, darstellt; R<sup>3</sup> C<sub>2</sub>-C<sub>3</sub>-Alkyl oder Allyl ist; R<sup>4</sup> zusammen mit dem Stickstoffatom, an das es gebunden ist, eine Piperidino- oder 4-N-(R<sup>6</sup>)-Piperazinyl-Gruppe bildet; R<sup>5</sup> H, NR<sup>7</sup>R<sup>8</sup> bedeutet; R<sup>6</sup> H, C<sub>1</sub>-C<sub>3</sub>-Alkyl, Hydroxy-C<sub>2</sub>-C<sub>3</sub>-alkyl, CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> oder C(NH)NR<sup>7</sup>R<sup>8</sup> darstellt; und R<sup>7</sup> und R<sup>8</sup> jeweils unabhängig H oder Methyl sind.

25

5. Verfahren nach Anspruch 4, wobei R<sup>1</sup> Methyl bedeutet; R<sup>2</sup> n-Propyl darstellt; R<sup>3</sup> Ethyl, n-Propyl oder Allyl ist; R<sup>4</sup> zusammen mit dem Stickstoffatom, an das es gebunden ist, eine 4-N-(R<sup>6</sup>)-Piperazinyl-Gruppe bildet; R<sup>5</sup> H bedeutet; und R<sup>6</sup> H, C<sub>1</sub>-C<sub>3</sub>-Alkyl oder 2-Hydroxyethyl darstellt.


30

6. Verfahren nach Anspruch 5, bei welchem die Verbindung der Formel (I) ausgewählt wird aus:  
 5-[2-Allyloxy-5-(4-methylpiperazinylsulfonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on;  
 5-[2-Ethoxy-5-(piperazinylsulfonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on;  
 5-[2-Ethoxy-5-(4-methylpiperazinylsulfonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on;  
 5-[2-Ethoxy-5-[4-(2-propyl)-piperazinylsulfonyl]-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on;  
 5-[2-Ethoxy-5-[4-(2-hydroxyethyl)-piperazinylsulfonyl]phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on;  
 1-Methyl-5-[5-(piperazinylsulfonyl)-2-n-propoxyphenyl]-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on; und  
 5-[5-[4-(2-Hydroxyethyl)-piperazinylsulfonyl]-2-n-propoxyphenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on,  
 und pharmazeutisch annehmbaren Salzen hievon.

50

55

7. Verbindung der Formel:




worin R<sup>1</sup> und R<sup>2</sup> wie in Anspruch 1 definiert sind, R<sup>3</sup> wie in Anspruch 1 definiert ist, und auch H bedeutet, und Y Chlor, Brom oder Fluor darstellt.

**Revendications**

20 Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Composé de formule :




dans laquelle :

- R<sup>1</sup> représente H, alkyle en C<sub>1</sub>-C<sub>3</sub>, cycloalkyle en C<sub>3</sub>-C<sub>5</sub> ou perfluororoalkyle en C<sub>1</sub>-C<sub>3</sub> ;
  - R<sup>2</sup> représente H, alkyle en C<sub>1</sub>-C<sub>6</sub> éventuellement substitué par OH, alcoxy en C<sub>1</sub>-C<sub>3</sub> ou cycloalkyle en C<sub>3</sub>-C<sub>6</sub>, ou perfluoroalkyle en C<sub>1</sub>-C<sub>3</sub> ;
  - R<sup>3</sup> représente alkyle en C<sub>1</sub>-C<sub>6</sub>, alkényle en C<sub>3</sub>-C<sub>6</sub>, alkynyle en C<sub>3</sub>-C<sub>6</sub>, cycloalkyle en C<sub>3</sub>-C<sub>7</sub>, perfluoroalkyle en C<sub>1</sub>-C<sub>6</sub> ou (cycloalkyle en C<sub>3</sub>-C<sub>6</sub>)alkyle en C<sub>1</sub>-C<sub>6</sub> ;
  - R<sup>4</sup> pris avec l'atome d'azote auquel il est lié complète un noyau pyrrolidinylique, pipéridino, morpholino ou 4-N-(R<sup>6</sup>)-pipérazinyle ;
  - R<sup>5</sup> représente H, alkyle en C<sub>1</sub>-C<sub>4</sub>, alcoxy en C<sub>1</sub>-C<sub>3</sub>, NR<sup>7</sup>R<sup>8</sup>, ou CONR<sup>7</sup>R<sup>8</sup> ;
  - R<sup>6</sup> représente H, alkyle en C<sub>1</sub>-C<sub>6</sub>, (alcoxy en C<sub>1</sub>-C<sub>3</sub>)alkyle en C<sub>2</sub>-C<sub>6</sub>, hydroxy(alkyle en C<sub>2</sub>-C<sub>6</sub>), (R<sup>7</sup>R<sup>8</sup>N)alkyle en C<sub>2</sub>-C<sub>6</sub>, (R<sup>7</sup>R<sup>8</sup>NCO)alkyle en C<sub>1</sub>-C<sub>6</sub>, CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> ou C(NH)NR<sup>7</sup>R<sup>8</sup> ;
  - R<sup>7</sup> et R<sup>8</sup> représentent chacun indépendamment H, alkyle en C<sub>1</sub>-C<sub>4</sub>, (alcoxy en C<sub>1</sub>-C<sub>3</sub>)alkyle en C<sub>2</sub>-C<sub>4</sub> ou hydroxy(alkyle en C<sub>2</sub>-C<sub>4</sub>) ;
- et ses sels pharmaceutiquement acceptables.

- 55 2. Composé selon la revendication 1, dans lequel R<sup>1</sup> représente H, méthyle ou éthyle ; R<sup>2</sup> représente alkyle en C<sub>1</sub>-C<sub>3</sub> éventuellement substitué par OH ou méthoxy ; R<sup>3</sup> représente alkyle en C<sub>2</sub>-C<sub>3</sub> ou allyle ; R<sup>4</sup> pris ensemble avec l'atome d'azote auquel il est lié complète un cycle pipéridino ou 4-N-(R<sup>6</sup>)-

pipérazinyle ; R<sup>5</sup> représente H, NR<sup>7</sup>R<sup>8</sup> ou CONR<sup>7</sup>R<sup>8</sup> ; R<sup>6</sup> représente H, alkyle en C<sub>1</sub>-C<sub>3</sub>, hydroxy-alkyle en C<sub>2</sub>-C<sub>3</sub>), CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> ou C(NH)NR<sup>7</sup>R<sup>8</sup> ; et R<sup>7</sup> et R<sup>8</sup> représentent chacun indépendamment H ou méthyle.

- 5     3. Composé selon la revendication 2, dans lequel R<sup>1</sup> représente méthyle ; R<sup>2</sup> représente n-propyle ; R<sup>3</sup> représente éthyle, n-propyle ou allyle ; R<sup>4</sup> pris ensemble avec l'atome d'azote auquel il est lié complète un cycle 4-N-(R<sup>6</sup>)-pipérazinyle ; R<sup>5</sup> représente H ; et R<sup>6</sup> représente H, alkyle en C<sub>1</sub>-C<sub>3</sub> ou 2-hydroxyéthyle.
- 10    4. Composé selon la revendication 3, caractérisé en ce qu'il est choisi parmi les suivants :  
       5-(2-allyloxy-5-(4-méthylpipérazinylsulfonyl)phényl)-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one ;  
       5-(2-éthoxy-5-(pipérazinylsulfonyl)phényl)-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one ;  
       5-(2-éthoxy-5-(4-méthylpipérazinylsulfonyl)phényl)-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one ;  
       5-{2-éthoxy-5-(4-(2-propyl)pipérazinylsulfonyl)phényl}-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one ;  
       5-{2-éthoxy-5-(4-(2-hydroxyéthyl)pipérazinylsulfonyl)phényl}-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one ;  
       1-méthyl-5-(5-(pipérazinylsulfonyl)-2-n-propoxyphényl)-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one ; et  
       5-{5-(4-(2-hydroxyéthyl)pipérazinylsulfonyl)-2-n-propoxyphényl}-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one,  
       et leurs sels pharmaceutiquement acceptables.
- 20    5. Composition pharmaceutique comprenant un composé de formule (I) ou un sel pharmaceutiquement acceptable d'un tel composé, tel que revendiqué dans l'une quelconque des revendications 1 à 4, avec un diluant ou un véhicule pharmaceutiquement acceptable.
- 30    6. Composé de formule (I) ou sel pharmaceutiquement acceptable d'un tel composé, tel que revendiqué dans l'une quelconque des revendications 1 à 4, pour une utilisation en médecine, en particulier pour le traitement de l'angine, de l'hypertension, des défaillances cardiaques et de l'athérosclérose.
- 35    7. Utilisation d'un composé de formule (I) ou d'un sel pharmaceutiquement acceptable d'un tel composé, tel que revendiqué dans l'une quelconque des revendications 1 à 4, pour fabriquer un médicament, en particulier pour le traitement de l'angine, de l'hypertension, des défaillances cardiaques, de l'athérosclérose, des attaques, des maladies vasculaires périphériques, des états d'obstruction partielle des vaisseaux sanguins, de l'asthme chronique, de la bronchite, de l'asthme allergique, de la rhinite allergique, du glaucome ou des maladies caractérisées par des désordres de la motilité intestinale.
- 40    8. Composé de formule :



dans laquelle R<sup>1</sup> et R<sup>2</sup> sont tels que revendiqués dans la revendication 1, R<sup>3</sup> est tel que revendiqué dans la revendication 1 et représente également H, et Y représente chloro, bromo ou fluoro.

**Revendications pour l'Etat contractant suivant : ES**


1. Procédé de préparation d'un composé de formule :

5

10

15

20



dans laquelle :

- R¹ représente H, alkyle en C<sub>1</sub>-C<sub>3</sub>, cycloalkyle en C<sub>3</sub>-C<sub>5</sub> ou perfluororoalkyle en C<sub>1</sub>-C<sub>3</sub> ;
- R² représente H, alkyle en C<sub>1</sub>-C<sub>6</sub> éventuellement substitué par OH, alcoxy en C<sub>1</sub>-C<sub>3</sub> ou cycloalkyle en C<sub>3</sub>-C<sub>6</sub>, ou perfluoroalkyle en C<sub>3</sub>-C<sub>6</sub> ;
- R³ représente alkyle en C<sub>1</sub>-C<sub>6</sub>, alkényle en C<sub>3</sub>-C<sub>6</sub>, alkynyle en C<sub>3</sub>-C<sub>6</sub>, cycloalkyle en C<sub>3</sub>-C<sub>7</sub>, perfluoroalkyle en C<sub>1</sub>-C<sub>3</sub> ou (cycloalkyle en C<sub>3</sub>-C<sub>6</sub>)alkyle en C<sub>1</sub>-C<sub>6</sub> ;
- R⁴ pris avec l'atome d'azote auquel il est lié complète un noyau pyrrolidinyle, pipéridino, morpholino ou 4-N-(R⁶)-pipérazinyle ;
- R⁵ représente H, alkyle en C<sub>1</sub>-C<sub>4</sub>, alcoxy en C<sub>1</sub>-C<sub>3</sub>, NR⁷R⁸, ou CONR⁷R⁸ ;
- R⁶ représente H, alkyle en C<sub>1</sub>-C<sub>6</sub>, (alcoxy en C<sub>1</sub>-C<sub>3</sub>)alkyle en C<sub>2</sub>-C<sub>6</sub>, hydroxy(alkyle en C<sub>2</sub>-C<sub>6</sub>), (R⁷R⁸N)alkyle en C<sub>2</sub>-C<sub>6</sub>, (R⁷R⁸NCO)alkyle en C<sub>1</sub>-C<sub>6</sub>, CONR⁷R⁸, CSNR⁷R⁸ ou C(NH)NR⁷R⁸ ;
- R⁷ et R⁸ représentent chacun indépendamment H, alkyle en C<sub>1</sub>-C<sub>4</sub>, (alcoxy en C<sub>1</sub>-C<sub>3</sub>)alkyle en C<sub>2</sub>-C<sub>4</sub> ou hydroxy(alkyle en C<sub>2</sub>-C<sub>4</sub>) ;


35

et ses sels pharmaceutiquement acceptables,  
qui consiste à faire réagir un composé de formule :

40


45

50



dans laquelle R¹, R² et R³ sont tels que précédemment définis, et Y représente chloro bromo ou fluoro, avec un composé de formule :

55



5

10 dans laquelle R<sup>4</sup> et R<sup>5</sup> sont tels que précédemment définis, et éventuellement à transformer le produit attendu en un sel pharmaceutiquement acceptable.

2. Procédé selon la revendication 1, dans lequel R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> et R<sup>5</sup> sont tels que revendiqués dans la revendication 1, et R<sup>3</sup> représente H, suivi d'une O-alkylation du phénol et de la transformation facultative du produit attendu en un sel pharmaceutiquement acceptable.
- 15 3. Procédé selon la revendication 1 ou 2, dans lequel R<sup>1</sup>, R<sup>4</sup> et R<sup>5</sup> sont tels que revendiqués dans la revendication 1, et R<sup>3</sup> est tel que revendiqué dans la revendication 1 ou 2, dans lequel R<sup>2</sup> comporte un substituant hydroxy protégé par un radical acétyle ou benzoyle, ledit groupe protecteur étant ultérieurement éliminé par une hydrolyse basique avant la transformation facultative du produit attendu en un sel pharmaceutiquement acceptable.
- 20 4. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel R<sup>1</sup> représente H, méthyle ou éthyle ; R<sup>2</sup> représente alkyle en C<sub>1</sub>-C<sub>3</sub> éventuellement substitué par OH ou méthoxy ; R<sup>3</sup> représente alkyle en C<sub>2</sub>-C<sub>3</sub> ou allyle ; R<sup>4</sup> pris ensemble avec l'atome d'azote auquel il est lié complète un cycle pipéridino ou 4-N-(R<sup>6</sup>)pipérazinyle ; R<sup>5</sup> représente H, NR<sup>7</sup>R<sup>8</sup> ou CONR<sup>7</sup>R<sup>8</sup> ; R<sup>6</sup> représente H, alkyle en C<sub>1</sub>-C<sub>3</sub>, hydroxy(alkyle en C<sub>2</sub>-C<sub>3</sub>), CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> ou C(NH)NR<sup>7</sup>R<sup>8</sup> ; et R<sup>7</sup> et R<sup>8</sup> représentent chacun indépendamment H ou méthyle.
- 25 5. Procédé selon la revendication 4, dans lequel R<sup>1</sup> représente méthyle ; R<sup>2</sup> représente n-propyle ; R<sup>3</sup> représente éthyle, n-propyle ou allyle ; R<sup>4</sup> pris ensemble avec l'atome d'azote auquel il est lié complète un cycle 4-N-(R<sup>6</sup>)-pipérazinyle ; R<sup>5</sup> représente H ; et R<sup>6</sup> représente H, alkyle en C<sub>1</sub>-C<sub>3</sub> ou 2-hydroxyéthyle.
- 30 6. Procédé selon la revendication 5, dans lequel ledit composé de formule (I) produit est choisi parmi :
  - 5-(2-allyloxy-5-(4-méthylpipérazinylsulfonyl)phényl)-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo-(4,3-d)pyrimidin-7-one ;
  - 5-(2-éthoxy-5-(pipérazinylsulfonyl)phényl)-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one ;
  - 40 5-(2-éthoxy-5-(4-méthylpipérazinylsulfonyl)phényl)-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one ;
  - 5-{2-éthoxy-5-(4-(2-propyl)pipérazinylsulfonyl)phényl}-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo-(4,3-d)pyrimidin-7-one ;
  - 45 5-{2-éthoxy-5-(4-(2-hydroxyéthyl)pipérazinylsulfonyl)phényl}-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one ;
  - 1-méthyl-5-(5-(pipérazinylsulfonyl)-2-n-propoxyphényl)-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one ; et
  - 50 5-{5-(4-(2-hydroxyéthyl)pipérazinylsulfonyl)-2-n-propoxyphényl}-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one,
 et leurs sels pharmaceutiquement acceptables.

50

55

**Revendications pour l'Etat contractant suivant : GR**


1. Procédé de préparation d'un composé de formule :

5

10

15

20



dans laquelle :

- R¹ représente H, alkyle en C<sub>1</sub>-C<sub>3</sub>, cycloalkyle en C<sub>3</sub>-C<sub>5</sub> ou perfluororoalkyle en C<sub>1</sub>-C<sub>3</sub> ;
- R² représente H, alkyle en C<sub>1</sub>-C<sub>6</sub> éventuellement substitué par OH, alcoxy en C<sub>1</sub>-C<sub>3</sub> ou cycloalkyle en C<sub>3</sub>-C<sub>6</sub>, ou perfluoroalkyle en C<sub>1</sub>-C<sub>3</sub> ;
- R³ représente alkyle en C<sub>1</sub>-C<sub>6</sub>, alkényle en C<sub>3</sub>-C<sub>6</sub>, alkynyle en C<sub>3</sub>-C<sub>6</sub>, cycloalkyle en C<sub>3</sub>-C<sub>7</sub>, perfluoroalkyle en C<sub>1</sub>-C<sub>6</sub> ou (cycloalkyle en C<sub>3</sub>-C<sub>6</sub>)alkyle en C<sub>1</sub>-C<sub>6</sub> ;
- R⁴ pris avec l'atome d'azote auquel il est lié complète un noyau pyrrolidinylique, pipéridino, morpholino ou 4-N-(R⁶)-pipérazinyle ;
- R⁵ représente H, alkyle en C<sub>1</sub>-C<sub>4</sub>, alcoxy en C<sub>1</sub>-C<sub>3</sub>, NR⁷R⁸, ou CONR⁷R⁸ ;
- R⁶ représente H, alkyle en C<sub>1</sub>-C<sub>6</sub>, (alcoxy en C<sub>1</sub>-C<sub>3</sub>)alkyle en C<sub>2</sub>-C<sub>6</sub>, hydroxy(alkyle en C<sub>2</sub>-C<sub>6</sub>), (R⁷R⁸N)alkyle en C<sub>2</sub>-C<sub>6</sub>, (R⁷R⁸NCO)alkyle en C<sub>1</sub>-C<sub>6</sub>, CONR⁷R⁸, CSNR⁷R⁸ ou C(NH)NR⁷R⁸ ;
- R⁷ et R⁸ représentent chacun indépendamment H, alkyle en C<sub>1</sub>-C<sub>4</sub>, (alcoxy en C<sub>1</sub>-C<sub>3</sub>)alkyle en C<sub>2</sub>-C<sub>4</sub> ou hydroxy(alkyle en C<sub>2</sub>-C<sub>4</sub>) ;


35

et ses sels pharmaceutiquement acceptables,  
qui consiste à faire réagir un composé de formule :

40


45

50



dans laquelle R¹, R² et R³ sont tels que précédemment définis, et Y représente chloro, bromo ou fluoro, avec un composé de formule :

55



10 dans laquelle R<sup>4</sup> et R<sup>5</sup> sont tels que précédemment définis, et éventuellement à transformer le produit attendu en un sel pharmaceutiquement acceptable.

- 15 2. Procédé selon la revendication 1, dans lequel R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> et R<sup>5</sup> sont tels que revendiqués dans la revendication 1, et R<sup>3</sup> représente H, suivi d'une O-alkylation du phénol et de la transformation facultative du produit attendu en un sel pharmaceutiquement acceptable.
- 20 3. Procédé selon la revendication 1 ou 2, dans lequel R<sup>1</sup>, R<sup>4</sup> et R<sup>5</sup> sont tels que revendiqués dans la revendication 1, et R<sup>3</sup> est tel que revendiqué dans la revendication 1 ou 2, dans lequel R<sup>2</sup> comporte un substituant hydroxy protégé par un radical acétyle ou benzoyle, ledit groupe protecteur étant ultérieurement éliminé par une hydrolyse basique avant la transformation facultative du produit attendu en un sel pharmaceutiquement acceptable.
- 25 4. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel R<sup>1</sup> représente H, méthyle ou éthyle ; R<sup>2</sup> représente alkyle en C<sub>1</sub>-C<sub>3</sub> éventuellement substitué par OH ou méthoxy ; R<sup>3</sup> représente alkyle en C<sub>2</sub>-C<sub>3</sub> ou allyle ; R<sup>4</sup> pris ensemble avec l'atome d'azote auquel il est lié complète un cycle pipéridino ou 4-N-(R<sup>6</sup>)pipérazinyle ; R<sup>5</sup> représente H, NR<sup>7</sup>R<sup>8</sup> ou CONR<sup>7</sup>R<sup>8</sup> ; R<sup>6</sup> représente H, alkyle en C<sub>1</sub>-C<sub>3</sub>, hydroxy(alkyle en C<sub>2</sub>-C<sub>3</sub>), CONR<sup>7</sup>R<sup>8</sup>, CSNR<sup>7</sup>R<sup>8</sup> ou C(NH)NR<sup>7</sup>R<sup>8</sup> ; et R<sup>7</sup> et R<sup>8</sup> représentent chacun indépendamment H ou méthyle.
- 30 5. Procédé selon la revendication 4, dans lequel R<sup>1</sup> représente méthyle ; R<sup>2</sup> représente n-propyle ; R<sup>3</sup> représente éthyle, n-propyle ou allyle ; R<sup>4</sup> pris ensemble avec l'atome d'azote auquel il est lié complète un cycle 4-N-(R<sup>6</sup>)-pipérazinyle ; R<sup>5</sup> représente H ; et R<sup>6</sup> représente H, alkyle en C<sub>1</sub>-C<sub>3</sub> ou 2-hydroxyéthyle.
- 35 6. Procédé selon la revendication 5, dans lequel ledit composé de formule (I) produit est choisi parmi :  
 5-(2-allyloxy-5-(4-méthylpipérazinylsulfonyl)phényl)-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo-(4,3-d)pyrimidin-7-one ;  
 5-(2-éthoxy-5-(pipérazinylsulfonyl)phényl)-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one ;  
 40 5-(2-éthoxy-5-(4-méthylpipérazinylsulfonyl)phényl)-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one ;  
 5-{2-éthoxy-5-(4-(2-propyl)pipérazinylsulfonyl)phényl}-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo-(4,3-d)pyrimidin-7-one ;  
 45 5-{2-éthoxy-5-(4-(2-hydroxyéthyl)pipérazinylsulfonyl)phényl}-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one ;  
 1-méthyl-5-(5-(pipérazinylsulfonyl)-2-n-propoxyphényl)-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one ; et  
 5-{5-(4-(2-hydroxyéthyl)pipérazinylsulfonyl)-2-n-propoxyphényl}-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one,  
 et leurs sels pharmaceutiquement acceptables.
- 50

7. Composé de formule :

5

10

15

20

25

30

35

40

45

50

55

